Committee for medicinal products for human use (CHMP)
Draft agenda for the meeting on 20-23 February 2017

Chair: Tomas Salmonson – Vice-Chair: Harald Enzmann
20 February 2017, 13:00 – 19:30, room 2A
21 February 2017, 08:30 – 19:30, room 2A
22 February 2017, 08:30 – 19:30, room 2A
23 February 2017, 08:30 – 15:00, room 2A

Health and safety information
In accordance with the Agency’s health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers
Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.

Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents
Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).
# Table of contents

1. **Introduction**
   
   1.1. Welcome and declarations of interest of members, alternates and experts ................. 8  
   1.2. Adoption of agenda ........................................................................................................ 8  
   1.3. Adoption of the minutes ................................................................................................ 8  

2. **Oral Explanations**
   
   2.1. Pre-authorisation procedure oral explanations ............................................................... 8  
       2.1.1. - dinutuximab beta - Orphan - EMEA/H/C/003918 ......................................................... 8  
       2.1.2. - nonacog beta pegol - Orphan - EMEA/H/C/004178 ...................................................... 8  
       2.1.3. - pentosan polysulfate sodium - Orphan - EMEA/H/C/004246 ......................................... 9  
   2.2. Re-examination procedure oral explanations ................................................................ 9  
   2.3. Post-authorisation procedure oral explanations ............................................................. 9  
   2.4. Referral procedure oral explanations ............................................................................ 9  

3. **Initial applications**
   
   3.1. Initial applications; Opinions ...................................................................................... 9  
       3.1.1. - emtricitabine / tenofovir disoproxil - EMEA/H/C/004686 .......................................... 9  
       3.1.2. - sodium zirconium cyclosilicate - EMEA/H/C/004029 ............................................... 9  
       3.1.3. - parathyroid hormone - Orphan - EMEA/H/C/003861 ..................................................... 9  
       3.1.4. - pemetrexed - EMEA/H/C/004488 ............................................................................... 10  
       3.1.5. - rituximab - EMEA/H/C/003903 .................................................................................. 10  
       3.1.6. - edoxaban - EMEA/H/C/004339 ................................................................................ 10  
       3.1.7. - rolapitant - EMEA/H/C/004196 ................................................................................ 10  
       3.1.8. - rituximab - EMEA/H/C/004729 ................................................................................ 10  
   3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable) ................................................................. 11  
       3.2.1. - anamorelin - EMEA/H/C/003847 .............................................................................. 11  
       3.2.2. - expanded human allogeneic mesenchymal adult stem cells extracted from adipose tissue - Orphan - ATMP - EMEA/H/C/004258 ................................................................. 11  
       3.2.3. - inotuzumab ozogamicin - Orphan - EMEA/H/C/004119 .............................................. 11  
       3.2.4. - cerliponase alfa - Orphan - EMEA/H/C/004065 ........................................................... 11  
       3.2.5. - spheroids of human autologous matrix-associated chondrocytes - ATMP - EMEA/H/C/002736 .......................................................... 12  
       3.2.6. trientine tetrahydrochloride - Orphan - EMEA/H/C/004005 ........................................... 12  
       3.2.7. - etanercept - EMEA/H/C/004192 ................................................................................ 12  
       3.2.8. - iloperidone - EMEA/H/C/004149 ................................................................................ 12  
       3.2.9. - febuxostat - EMEA/H/C/004374 .................................................................................. 13  
       3.2.10. - dinutuximab beta - Orphan - EMEA/H/C/003918 ....................................................... 13
3.2.11. - sarilumab - EMEA/H/C/004254
3.2.12. - masitinib - Orphan - EMEA/H/C/004159
3.2.13. - pentosan polysulfate sodium - Orphan - EMEA/H/C/004246
3.2.14. - cariprazine - EMEA/H/C/002770
3.2.15. - dimethyl fumarate - EMEA/H/C/002157
3.2.16. - carglumic acid - EMEA/H/C/004019
3.2.17. - patiromer sorbitex calcium - EMEA/H/C/004180

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

3.3.1. - plitidepsin - Orphan - EMEA/H/C/004354
3.3.2. - avelumab - Orphan - EMEA/H/C/004338
3.3.3. - trastuzumab - EMEA/H/C/002575
3.3.4. - cenegermin - Orphan - EMEA/H/C/004209
3.3.5. - insulin glargine - EMEA/H/C/004280
3.3.6. - beclometasone dipropionate anhydrous / formoterol fumarate dihydrate / glycopyrronium bromide - EMEA/H/C/004257
3.3.7. - niraparib - Orphan - EMEA/H/C/004249
3.3.8. - buprenorphine / naloxone - EMEA/H/C/004407

3.4. Update on on-going initial applications for Centralised procedure

3.4.1. - prasterone - EMEA/H/C/004138
3.4.2. - velmanase alfa - Orphan - EMEA/H/C/003922
3.4.3. - miglustat - EMEA/H/C/004366
3.4.4. - tigecycline - EMEA/H/C/004419
3.4.5. - human IgG1 monoclonal antibody specific for human interleukin-1 alpha - EMEA/H/C/004388

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

3.6. Initial applications in the decision-making phase

3.7. Withdrawals of initial marketing authorisation application


4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1. Esbriet - pirfenidone - Orphan - EMEA/H/C/002154/X/0035/G
4.1.2. Nexium Control - esomeprazole - EMEA/H/C/002618/X/0016
4.1.3. Pergoveris - follitropin alfa / lutropin alfa - EMEA/H/C/000714/X/0047

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

4.2.1. Celsentri - maraviroc - EMEA/H/C/000811/X/0046/G

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question
4.3.1. Benlysta - belimumab - EMEA/H/C/002015/X/0046/G .................................................. 19
4.3.2. Exjade - deferasirox - Orphan - EMEA/H/C/000670/X/0054 ..................................... 19
4.3.3. Kuvan - sapropterin - Orphan - EMEA/H/C/000943/X/0047 ................................... 19
4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008 ................................................................. 20
4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008 .............................. 20

5. **Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008** .......................... 20

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information .................................................................................................................. 20
5.1.1. Darzalex - daratumumab - Orphan - EMEA/H/C/004077/II/0002 ......................... 20
5.1.2. Faslodex - fulvestrant - EMEA/H/C/000540/II/0057 ............................................. 20
5.1.3. Pegasys - peginterferon alfa-2a - EMEA/H/C/000395/II/0091 ............................ 21
5.1.4. Raxone - idebenone - Orphan - EMEA/H/C/003834/II/0003 ............................... 21
5.1.5. Sovaldi - sofosbuvir - EMEA/H/C/002798/II/0036 ............................................. 21
5.1.6. Stivarga - regorafenib - EMEA/H/C/002573/II/0020 ......................................... 22
5.1.7. Tasigna - nilotinib - Orphan - EMEA/H/C/000798/II/0084/G ......................... 22
5.1.8. Truvada - emtricitabine / tenofovir disoproxil - EMEA/H/C/000594/II/0131 . 22
5.1.9. Victoza - liraglutide - EMEA/H/C/001026/II/0042 ........................................... 22
5.1.10. Mekinist Tafinlar – trametinib dabrafenib - EMEA/H/C/WS0996 .................... 23

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 .......................... 24
5.2.1. BeneFIX - nonacog alfa - EMEA/H/C/000139/II/0141 ..................................... 24

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 ........................................... 24

6. **Ancillary medicinal substances in medical devices** .............................................. 24

6.1. Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions ......................................................... 24
6.2. Update of Ancillary medicinal substances in medical devices ............................. 24

7. **Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)** ......................................................................................................................... 24

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use) 24

8. **Pre-submission issues** ....................................................................................... 24

8.1. Pre-submission issue ........................................................................................ 24
8.2. Priority Medicines (PRIME) ............................................................................. 24
8.2.1. List of applications received ........................................................................... 25
8.2.2. Recommendation for PRIME eligibility

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Vectibix - panitumumab - EMEA/H/C/000741/II/0080

9.1.2. Tagrisso - osimertinib - EMEA/H/C/004124/II/0009/G

10. Referral procedures


10.1.1. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: Canaglifozin – INVOKANA (CAP); canagliflozin, metformin – VOKANAMET (CAP); dapaglifozin – EDISTRIDE (CAP); FORXIGA (CAP); dapaglifozin, metformin – XIGDUO (CAP), EBYMECT (CAP); empaglifozin – JARDIANCE (CAP); empaglifozin, metformin – SYNJARDY (CAP) - EMEA/H/A-20/1442

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

10.2.1. Desloratadine-containing products - desloratadine - EMEA/H/A-5(3)/1431

10.3. Procedure under Articles 5(2) and 10 of the Regulation (EC) No 726/2004

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

10.4.1. Paracomb 500mg/150mg film coated tablets - Paracetamol/Ibuprofen 500 mg/150 mg Paracetamol and Ibuprofen - EMEA/H/1447


10.5.1. Haldol and associated names - haloperidol - EMEA/H/A-30/1393

10.5.2. Haldol decanoate and associated names – haloperidol - EMEA/H/A-30/1405

10.5.3. Saroten and associated names - amitriptyline - EMEA/H/A-30/1430


10.6.1. Symbioflor 2, Escherichia Coli bacteria (cells and autolysate) - EMEA/H/A-31/1441

10.6.2. Vancomycin containing products – (vancomycin) - EMEA/H/A-31/1440


10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) (EC) No 1084/2003


10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) No 1234/2008

10.11.1. Cardioxane - Dexrazoxane – EMEA/H/A-13/1453

11. Pharmacovigilance issue

11.1. Early Notification System

12. Inspections

12.1. GMP inspections
12.2. GCP inspections ........................................................................................................ 30
12.3. Pharmacovigilance inspections .................................................................................. 30
12.4. GLP inspections ........................................................................................................ 30

13. Innovation Task Force 30
13.1. Minutes of Innovation Task Force .............................................................................. 30
13.2. Innovation Task Force briefing meetings ....................................................................... 31
13.4. Nanomedicines activities ............................................................................................. 31

14. Organisational, regulatory and methodological matters 31
14.1. Mandate and organisation of the CHMP ..................................................................... 31
14.1.1. CHMP meetings to be held in Valletta 28 February - 3 March 2017 under the Maltese Presidency of the Council of the European Union ......................................................... 31
14.1.2. Survey to committee members on the service provided by the Scientific Committees Service .......................................................................................................................... 31
14.1.3. Report on Data-sharing initiative in Alzheimer’s disease ............................................. 32
14.1.4. CHMP and ORGAM meeting dates 2019-2021 .......................................................... 32
14.1.5. Presentation on Experience of PAES ........................................................................... 32
14.1.6. ATMP guideline on safety and efficacy follow-up and risk management (EMA/CHMP/65416/2016) ............................................................................................................. 32
14.1.7. Overview on current activities in Africa ....................................................................... 32
14.2. Coordination with EMA Scientific Committees ............................................................ 32
14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC) ............................................. 32
14.2.2. Committee for Advanced Therapies (CAT) ................................................................. 32
14.2.3. Committee for Herbal Medicinal Products (HMPC) ..................................................... 33
14.2.4. Paediatric Committee (PDCO) ................................................................................... 33
14.2.5. Committee for Orphan Medicinal Products (COMP) ................................................... 33
14.2.6. Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) ................................................................................................................. 33
14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups ........... 33
14.3.1. Scientific Advice Working Party (SAWP) ..................................................................... 33
14.3.2. Name Review Group (NRG) ........................................................................................ 34
14.3.3. Blood Products Working Party (BPWP) ....................................................................... 34
14.3.4. Biologics Working Party (BWP) ................................................................................... 34
14.3.5. Gastroenterology Drafting Group (GDG) ..................................................................... 34
14.3.6. Pharmacogenomics Working Party (PGWP) ............................................................... 34
14.3.7. Vaccines Working Party (VWP) ................................................................................... 34
14.3.8. Rheumatology/Immunology Working Party (RIWP) ...................................................... 35
14.3.9. Oncology Working Party (ONCWP) ............................................................................ 35
14.3.10. Antimicrobial Advice ad hoc Expert Group (AMEG) .................................................. 35
14.3.11. Quality Working Party (QWP) .................................................................................... 35
14.4. Cooperation within the EU regulatory network ........................................... 36
14.5. Cooperation with International Regulators .............................................. 36
14.5.1. EMA/FDA strategic document on Gaucher disease ............................... 36
14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee ......................................................... 36
14.7. CHMP work plan ........................................................................................ 36
14.7.1. CHMP 2017 Work Plan ........................................................................... 36
14.8. Planning and reporting .............................................................................. 36
14.9. Others ........................................................................................................ 36

15. Any other business .......................................................................................... 36
15.1. AOB topic ................................................................................................ 36
15.1.1. Operation and Relocation Preparedness - Workstream 2 - Operational Preparedness ...... 36

16. Explanatory notes ......................................................................................... 37
1. **Introduction**

1.1. **Welcome and declarations of interest of members, alternates and experts**

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session to be held 20-23 February 2017. See February 2017 CHMP minutes (to be published post March 2017 CHMP meeting).

1.2. **Adoption of agenda**

CHMP agenda for 20-23 February 2017

1.3. **Adoption of the minutes**

CHMP minutes for 23-26 January 2016.

2. **Oral Explanations**

2.1. **Pre-authorisation procedure oral explanations**

2.1.1. **- dinutuximab beta - Orphan - EMEA/H/C/003918**

APEIRON Biologics AG; treatment of neuroblastoma

Scope: Oral explanation to be held on 22 February 2017 at time 09:00

**Action**: For adoption


2.1.2. **- nonacog beta pegol - Orphan - EMEA/H/C/004178**

Novo Nordisk A/S; treatment of haemophilia B

Scope: Oral explanation

**Action**: Oral explanation to be held on 21 February 2017 at time 09:00


BWP report
2.1.3. - pentosan polysulfate sodium - Orphan - EMEA/H/C/004246

bene-Arzneimittel GmbH; treatment of Interstitial Cystitis

Scope: Oral explanation

**Action**: Oral explanation to be held on 20 February 2017 at time 16:00


2.2. **Re-examination procedure oral explanations**

2.3. **Post-authorisation procedure oral explanations**

2.4. **Referral procedure oral explanations**

3. **Initial applications**

3.1. **Initial applications; Opinions**

3.1.1. - emtricitabine / tenofovir disoproxil - EMEA/H/C/004686

treatment of HIV-1 infection

Scope: Opinion

**Action**: For adoption

3.1.2. - sodium zirconium cyclosilicate - EMEA/H/C/004029

for the treatment of hyperkalaemia

Scope: Opinion

**Action**: For adoption


3.1.3. - parathyroid hormone - Orphan - EMEA/H/C/003861

NPS Pharma Holdings Limited; treatment of hypoparathyroidism

Scope: Opinion

**Action**: For adoption
List of Questions adopted on 26.03.2015.

BWP report

3.1.4. **- pemetrexed - EMEA/H/C/004488**

treatment of malignant pleural mesothelioma and non-small cell lung cancer
Scope: Opinion
**Action**: For adoption

3.1.5. **- rituximab - EMEA/H/C/003903**

treatment of Non-Hodgkin's lymphoma (NHL), Chronic lymphocytic leukaemia (CLL), Rheumatoid arthritis and Granulomatosis with polyangiitis and microscopic polyangiitis
Scope: Opinion
**Action**: For adoption
List of Questions adopted on 15.09.2016.
BWP report

3.1.6. **- edoxaban - EMEA/H/C/004339**

prevention of stroke; embolism and treatment of venous thromboembolism
Scope: Opinion
**Action**: For adoption

3.1.7. **- rolapitant - EMEA/H/C/004196**

prevention of nausea and vomiting
Scope: Opinion
**Action**: For adoption

3.1.8. **- rituximab - EMEA/H/C/004729**

treatment of Non-Hodgkin's lymphoma (NHL), Chronic lymphocytic leukaemia (CLL), Rheumatoid arthritis and Granulomatosis with polyangiitis and microscopic polyangiitis
Scope: Opinion

**Action**: For adoption

### 3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

#### 3.2.1. - anamorelin - EMEA/H/C/003847

TREATMENT OF ANOREXIA, CACHEXIA OR UNINTENDED WEIGHT LOSS IN ADULT PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)

Scope: Day 180 list of outstanding issue

**Action**: For adoption


#### 3.2.2. - expanded human allogeneic mesenchymal adult stem cells extracted from adipose tissue - Orphan - ATMP - EMEA/H/C/004258

TIGENIX, S.A.U.; treatment of complex perianal fistula(s)

Scope: Day 180 list of outstanding issue

**Action**: For adoption

List of Questions adopted on 15.07.2016.

BWP report

#### 3.2.3. - inotuzumab ozogamicin - Orphan - EMEA/H/C/004119

Pfizer Limited; treatment B-cell precursor acute lymphoblastic leukaemia (ALL)

Scope: Day 180 list of outstanding issue

**Action**: For adoption

List of Questions adopted on 15.09.2016.

BWP report

#### 3.2.4. - cerliponase alfa - Orphan - EMEA/H/C/004065

Accelerated assessment

BioMarin International Limited; treatment of neuronal ceroid lipofuscinosis type 2

Scope: Day 180 list of outstanding issue, list of experts for the Brineura ad hoc expert group meeting adopted via written procedure
**Action**: For adoption

3.2.5. **- spheroids of human autologous matrix-associated chondrocytes - ATMP - EMEA/H/C/002736**

- treatment of cartilage defects
Scope: Day 180 list of outstanding issue
**Action**: For adoption
BWP report

3.2.6. **trientine tetrahydrochloride - Orphan - EMEA/H/C/004005**

- GMP-Orphan SA; Wilson’s disease
Scope: Day 180 list of outstanding issue/Oral Explanation
**Action**: For adoption

3.2.7. **- etanercept - EMEA/H/C/004192**

- treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis, plaque psoriasis and paediatric plaque psoriasis
Scope: Day 180 list of outstanding issue
**Action**: For adoption
List of Questions adopted on 01.04.2016.
BWP report

3.2.8. **- iloperidone - EMEA/H/C/004149**

- treatment of schizophrenia
Scope: Day 180 list of outstanding issue
**Action**: For adoption
3.2.9. - febuxostat - EMEA/H/C/004374

treatment of hyperuricaemia
Scope: Day 180 list of outstanding issue
**Action:** For adoption
List of Questions adopted on 15.09.2016.

3.2.10. - dinutuximab beta - Orphan - EMEA/H/C/003918

APEIRON Biologics AG; treatment of neuroblastoma
Scope: Day 180 list of outstanding issue
**Action:** For adoption

3.2.11. - sarilumab - EMEA/H/C/004254

treatment of active rheumatoid arthritis
Scope: Day 180 list of outstanding issue
**Action:** For adoption
List of Questions adopted on 10.11.2016.
BWP report

3.2.12. - masitinib - Orphan - EMEA/H/C/004159

AB Science; treatment of mastocytosis
Scope: Day 180 list of outstanding issue
**Action:** For adoption
List of Questions adopted on 15.09.2016.

3.2.13. - pentosan polysulfate sodium - Orphan - EMEA/H/C/004246

bene-Arzneimittel GmbH; treatment of Interstitial Cystitis
Scope: Day 180 list of outstanding issue
**Action:** For adoption
3.2.14. - cariprazine - EMEA/H/C/002770

treatment of schizophrenia
Scope: Day 180 list of outstanding issue

**Action**: For adoption

3.2.15. - dimethyl fumarate - EMEA/H/C/002157

treatment of moderate to severe plaque psoriasis in adults in need of systemic drug therapy
Scope: Day 180 list of outstanding issue

**Action**: For adoption

3.2.16. - carglumic acid - EMEA/H/C/004019

treatment of hyperammoniemia
Scope: Day 180 list of outstanding issue

**Action**: For adoption
List of Questions adopted on 15.09.2016.

3.2.17. - patiromer sorbitex calcium - EMEA/H/C/004180

treatment of hyperkalaemia
Scope: Day 180 list of outstanding issue

**Action**: For adoption
List of Questions adopted on 15.09.2016.

3.3. **Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)**

3.3.1. - plitidepsin - Orphan - EMEA/H/C/004354

Pharma Mar, S.A.; treatment of multiple myeloma
Scope: Day 120 list of questions

**Action**: For adoption

3.3.2. - avelumab - Orphan - EMEA/H/C/004338

Merck Serono Europe Limited; treatment of Merkel cell carcinoma (MCC)
Scope: Day 120 list of questions

**Action**: For adoption

BWP report

### 3.3.3. - trastuzumab - EMEA/H/C/002575

treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Scope: Day 120 list of questions

**Action**: For adoption

BWP report

### 3.3.4. - cenegermin - Orphan - EMEA/H/C/004209

Accelerated assessment

Dompe farmaceutici s.p.a.; treatment of neurotrophic keratitis

Scope: Day 120 list of questions

**Action**: For adoption

BWP report

### 3.3.5. - insulin glargine - EMEA/H/C/004280

treatment of diabetes mellitus

Scope: Day 120 list of questions

**Action**: For adoption

### 3.3.6. - beclometasone dipropionate anhydrous / formoterol fumarate dihydrate / glycopyrronium bromide - EMEA/H/C/004257

for the symptomatic treatment and reduction of exacerbations in adult patients with chronic obstructive pulmonary disease (COPD) with airflow limitation and who are at risk of exacerbations

Scope: Day 120 list of questions

**Action**: For adoption

### 3.3.7. - niraparib - Orphan - EMEA/H/C/004249

TesarO UK Limited; Treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer

Scope: Day 120 list of questions

**Action**: For adoption
3.3.8. **- buprenorphine / naloxone - EMEA/H/C/004407**

Treatment for opioid drug dependence

Scope: Day 120 list of questions

**Action**: For adoption

3.4. **Update on on-going initial applications for Centralised procedure**

3.4.1. **- prasterone - EMEA/H/C/004138**

Treatment of vulvovaginal atrophy

Scope: Letter from the applicant dated 14 February 2017 requesting an extension of clock stop to respond to the List of Outstanding Issues adopted on 26 January 2017

**Action**: For adoption


3.4.2. **- velmanase alfa - Orphan - EMEA/H/C/003922**

Chiesi Farmaceutici S.p.A.; for long-term enzyme replacement therapy in patients with alpha-mannosidosis

Scope: Letter from the applicant dated 8 February 2017 requesting an extension of clock stop to respond to the List of Questions adopted on 26 January 2017

**Action**: For adoption

List of Questions adopted on 26.01.2017

3.4.3. **- miglustat - EMEA/H/C/004366**

Treatment of Gaucher disease

Scope: Letter from the applicant dated 8 February 2017 requesting an extension of clock stop to respond to the List of Questions adopted on 15 December 2016.

**Action**: For adoption


3.4.4. **- tigecycline - EMEA/H/C/004419**

Treatment of: - complicated skin and soft tissue infections, excluding diabetic foot infections

Scope: Letter from the applicant dated 7 February 2017 requesting an extension of clock stop to respond to the List of Questions adopted on 13 October 2016

**Action**: For adoption
List of Questions adopted on 13.10.2016

3.4.5.  - human IgG1 monoclonal antibody specific for human interleukin-1 alpha - EMEA/H/C/004388

treatment of metastatic colorectal cancer
Action: For information

3.5.  Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

3.6.  Initial applications in the decision-making phase

3.7.  Withdrawals of initial marketing authorisation application


4.1.  Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1.  Esbriet - pirfenidone - Orphan - EMEA/H/C/002154/X/0035/G

Roche Registration Limited
Rapporteur: Greg Markey, Co-Rapporteur: David Lyons, PRAC Rapporteur: Julie Williams
Scope: "Extension application to introduce a new pharmaceutical form associated with 3 new strengths (267mg, 534mg and 801mg film-coated tablets).
Action: For adoption

4.1.2.  Nexium Control - esomeprazole - EMEA/H/C/002618/X/0016

Pfizer Consumer Healthcare Ltd
Rapporteur: Romaldas Mačiulaitis, Co-Rapporteur: Robert James Hemmings, PRAC
Rapporteur: Simona Kudeliene
Scope: "Extension application to introduce a new pharmaceutical form (Gastro-resistant capsule, hard)"

**Action**: For adoption

List of Questions adopted on 10.11.2016.

### 4.1.3. Pergoveris - follitropin alfa / lutropin alfa - EMEA/H/C/000714/X/0047

Merck Serono Europe Limited

Rapporteur: Nithyanandan Nagercoil, PRAC Rapporteur: Julie Williams

Scope: "Extension application to introduce a new pharmaceutical form (solution for injection) associated with 3 strengths of (300 IU + 150 IU)/ 0.48 ml, (450 IU + 225 IU)/ 0.72 ml and (900 IU + 450 IU)/ 1.44 ml.”

**Action**: For adoption

List of Questions adopted on 10.11.2016.

### 4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

#### 4.2.1. Celsentri - maraviroc - EMEA/H/C/000811/X/0046/G

ViiV Healthcare UK Limited

Rapporteur: Filip Josephson, Co-Rapporteur: Bruno Sepodes, PRAC Rapporteur: Qun-Ying Yue

Scope: "Extension application to introduce new pharmaceutical form (20mg/ml oral solution) and 2 new strengths of film-coated tablets (25mg and 75mg) to the currently approved presentations for Celsentri, grouped with extension of indication to include paediatric use (2 to 18 years).

As a consequence, sections 4.2 and 4.4 of the SmPC are updated to detail posology in paediatric patients and to update the safety information, respectively.

The Package Leaflet and Labelling are updated in accordance.

Furthermore, the PI is brought in line with the latest QRD template version 10.”

**Action**: For adoption

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

4.3.1. Benlysta - belimumab - EMEA/H/C/002015/X/0046/G

Glaxo Group Ltd

Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga

Scope: “Extension application to introduce a new pharmaceutical form (solution for injection), a new strength (200 mg) and a new route of administration (subcutaneous use) grouped with a type II variation (C.I.4) to include changes in the Product Information.”

Action: For adoption

4.3.2. Exjade - deferasirox - Orphan - EMEA/H/C/000670/X/0054

Novartis Europharm Ltd

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Claire Ferard

Scope: “Extension application for a new pharmaceutical form (Exjade 90, 180 and 360 mg granules).”

Action: For adoption

4.3.3. Kuvan - sapropterin - Orphan - EMEA/H/C/000943/X/0047

BioMarin International Limited

Rapporteur: Patrick Salmon, PRAC Rapporteur: Almath Spooner

Scope: “Extension application to introduce a new pharmaceutical form associated with new strength (100 mg and 500 mg powder for oral solution).”

Action: For adoption
4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Darzalex - daratumumab - Orphan - EMEA/H/C/004077/II/0002

Janssen-Cilag International NV

Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension of Indication for Darzalex in the treatment of adult patients with multiple myeloma who have received at least 1 prior therapy. As a consequence, sections 4.2, 4.4, 4.5, 5.1 and 5.2 of the SmPC are updated in order to update the information on posology, warnings, interactions, efficacy and pharmacokinetics. A new warning is introduced in section 4.4 regarding neutropenia/thrombocytopenia induced by background therapy.

Annex II is updated to remove all the specific obligations following submissions of the final results of studies MMY3003 and MMY3004.

The Package Leaflet and Risk Management Plan (RMP version 2) are updated in accordance. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.

Action: For adoption

Request for Supplementary Information adopted on 15.12.2016.

5.1.2. Faslodex - fulvestrant - EMEA/H/C/000540/II/0057

AstraZeneca UK Ltd

Rapporteur: Filip Josephson, Co-Rapporteur: Tuomo Lapveteläinen, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of Indication to include the treatment of postmenopausal women with locally advanced or metastatic breast cancer who have not received prior endocrine therapy for Faslodex. As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated in order to update the safety and pharmacodynamics information. The Package Leaflet is updated in
In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce clarifications in the SmPC.”

**Action:** For adoption

---

### 5.1.3. Pegasys - peginterferon alfa-2a - EMEA/H/C/000395/II/0091

Roche Registration Limited

**Rapporteur:** Filip Josephson, PRAC Rapporteur: Qun-Ying Yue

**Scope:** “Extension of Indication to include paediatric patients from 3 to less than 18 years of age with Chronic Hepatitis B in the immune-active phase for Pegasys.

As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated in order to add efficacy and safety information from study YV25718. The Package Leaflet is updated in accordance.

An updated EU RMP (version 8.0) is included in this application.”

**Action:** For adoption

---

### 5.1.4. Raxone - idebenone - Orphan - EMEA/H/C/003834/II/0003

Santhera Pharmaceuticals (Deutschland) GmbH

**Rapporteur:** John Joseph Borg, Co-Rapporteur: Andrea Laslop, PRAC Rapporteur: Carmela Macchiarulo

**Scope:** “Extension of indication to include treatment of patients with Duchenne muscular dystrophy in whom respiratory function has started to decline and who are currently not taking concomitant glucocorticoids. Raxone can be used in patients previously treated with glucocorticoids or in patients in whom glucocorticoid treatment is not desired, not tolerated or is contraindicated.”

**Action:** For adoption

Request for Supplementary Information adopted on 15.09.2016.

---

### 5.1.5. Sovaldi - sofosbuvir - EMEA/H/C/002798/II/0036

Gilead Sciences International Ltd

**Rapporteur:** Filip Josephson, Co-Rapporteur: Alar IRS, PRAC Rapporteur: Rafe Suvarna

**Scope:** “Extension of indication to add treatment of chronic hepatitis C in adolescents aged 12 to <18 years.

As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated in order to add information on posology, warnings, safety, efficacy and pharmacokinetics.

The Package Leaflet and Risk Management Plan (RMP version 5.0) are updated in accordance.

In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.

Furthermore, the Product Information is brought in line with the latest QRD template version 10.”
5.1.6. **Stivarga - regorafenib - EMEA/H/C/002573/II/0020**

Bayer Pharma AG

Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Sabine Straus

Scope: "Extension of indication of Stivarga to include treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with one systemic therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the EU SmPC are updated. The package leaflet and RMP (version 5.0) have been updated accordingly. Furthermore, the PI is brought in line with the latest QRD template version 10.0."

**Action**: For adoption

5.1.7. **Tasigna - nilotinib - Orphan - EMEA/H/C/000798/II/0084/G**

Novartis Europharm Ltd

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Harald Enzmann, PRAC Rapporteur: Doris Stenver

Scope: "This grouped variation application consists of three Type II variation applications as follows:
- Update of the 150 mg SmPC sections 4.1, 4.2, 4.4, 4.8 and 5.1, and Package Leaflet based on the results from study CAMN107I2201 (ENESTfreedom): A Phase II, single-arm study evaluating nilotinib treatment discontinuation (treatment-free remission (TFR)) in newly-diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase (Ph+ CML-CP) who achieved a sustained deep molecular response.
- Update of the 150 mg and 200 mg Tasigna SmPC sections 4.1, 4.2, 4.4, 4.8 and 5.1, and Package Leaflet based on the results from study CAMN107A2408 (ENESTop): A Phase II, single-arm study evaluating nilotinib treatment discontinuation (treatment-free remission (TFR)) in patients with Ph+ CML-CP who achieved a sustained deep molecular response on nilotinib treatment after switching from imatinib treatment.
- Update of the 200 mg Tasigna SmPC sections 4.8 and 5.1, based on the results from study CAMN107A2405 (ENESTcmr): A Phase III open-label, randomised study to evaluate nilotinib or imatinib treatment in patients with Ph+ CML-CP who have not achieved a deep molecular response after previous imatinib therapy.

Additional changes to the labelling are proposed to comply with the latest QRD template version 10.

An updated RMP, version 16, is also provided in this application."

**Action**: For adoption

Request for Supplementary Information adopted on 13.10.2016.

5.1.8. **Truvada - emtricitabine / tenofovir disoproxil - EMEA/H/C/000594/II/0131**

Gilead Sciences International Ltd
Rapporteur: Greg Markey, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Julie Williams

Scope: "Extension of Indication to include treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years for Truvada.

As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated.

The Package Leaflet and the Risk Management plan (v.13) are updated in accordance."

Action: For adoption

Request for Supplementary Information adopted on 10.11.2016.

5.1.9. Victoza - liraglutide - EMEA/H/C/001026/II/0042

Novo Nordisk A/S

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Hanne Lomholt Larsen, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of Indication to include a new indication/population in Section 4.1 of the SmPC for Victoza.

As a consequence, sections 4.2, 4.4, 4.7, 4.8, 5.1 and 6.5 of the SmPC are updated to add warnings and update the safety information based on the findings of the LEADER (EX2211-3748) clinical study results, which constitutes the data set for the application. The Package Leaflet and Labelling (sections 17 and 18) are updated in accordance.

Updates to the liraglutide RMP based on the LEADER study results are also proposed: RMP Version 27 was submitted with the application, showing the proposed RMP changes."

Action: For adoption

5.1.10. Mekinist Tafinlar – trametinib dabrafenib - EMEA/H/C/WS0996

Novartis Europharm Ltd

Lead Rapporteur: Filip Josephson, Lead Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of indication to include the combination treatment with trametinib and dabrafenib of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600 mutation. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 5.3 of the Mekinist and Tafinlar SmPC are updated. The Package Leaflet and RMP are updated accordingly. In addition, the Worksharing applicant (WSA) took the opportunity to align the SmPCs of Mekinist and Tafinlar. Furthermore, the Product Information is brought in line with the latest QRD template version 10."

Action: For adoption

Request for Supplementary Information adopted on 10.11.2016.
5.2. **Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008**

5.2.1. **BeneFIX - nonacog alfa - EMEA/H/C/000139/II/0141**

MAH: Pfizer Limited
Rapporteur: Jan Mueller-Berghaus
Scope: "Update of section 5.2 of the SmPC in order to update the information based on PK data from study B1821048. This study reported PK from an extended collection time beyond the 72 hours previously used in all other BeneFIX studies, to 96 hours, after BeneFIX administration."

Letter dated 17.02.2017 informing about the withdrawal of the variation application.

**Action**: For information

5.3. **Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008**

6. **Ancillary medicinal substances in medical devices**

6.1. **Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions**

6.2. **Update of Ancillary medicinal substances in medical devices**

7. **Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)**

7.1. **Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)**

8. **Pre-submission issues**

8.1. **Pre-submission issue**

8.2. **Priority Medicines (PRIME)**

Disclosure of information related to priority medicines cannot be released at present time as
8.2.1. List of applications received

**Action:** For information

8.2.2. Recommendation for PRIME eligibility

**Action:** For adoption

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Vectibix - panitumumab - EMEA/H/C/000741/II/0080

MAH: Amgen Europe B.V.

Rapporteur: Robert James Hemmings, PRAC Rapporteur: Julie Williams

Scope: "Update of Annex II in order to provide the results of biomarker analyses from the Vectibix clinical programme including Study 20080763 (according to Supplementary Statistical Analysis Plan dated 20 September 2013), Study 20070820 and Study 20060447. The data submitted are in fulfilment of Annex II obligation ANX017. The Risk Management Plan (version 21.0) has been updated accordingly. The requested variation proposed amendments to Annex II and the Risk Management Plan."

Request for Supplementary Information adopted on 10.11.2016.

**Action:** For adoption

9.1.2. Tagrisso - osimertinib - EMEA/H/C/004124/II/0009/G

MAH: AstraZeneca AB

Rapporteur: Aranzazu Sancho-Lopez, PRAC Rapporteur: Sabine Straus

Scope: "Update of SmPC sections 4.2, 4.4, 4.8, 5.1 and 5.2 based on the results from study D5160C00003 (AURA3) and the updated CSRs for studies D5160C00001 (AURAex) and D5160C00002 (AURA2). The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to make editorial changes in the SmPC and Package Leaflet. The application included an updated RMP version 6.0. The provision of the CSR from study AURA3 addresses the Specific Obligation for Tagrisso and hence the MAH requests the conversion from a Conditional Marketing Authorisation to a Marketing Authorisation not subject to Specific Obligations."

Request for Supplementary Information adopted on 15.12.2016.
Action: For adoption

See also B.5.3

10. Referral procedures


10.1.1. Sodium-glucose co-transporter 2 (SGLT2) inhibitors:
Canagliflozin – INVOKANA (CAP); canagliflozin, metformin – VOKANAMET (CAP);
dapagliflozin – EDISTRIDE (CAP), FORXIGA (CAP); dapagliflozin, metformin –
XIGDUO (CAP), EBYMECT (CAP); empagliflozin – JARDIANE (CAP); empagliflozin,
metformin – SYNJARDY (CAP) - EMEA/H/A-20/1442

Applicant: Janssen-Cilag International N.V. (Invokana, Vokanamet); AstraZeneca AB
(Edistride, Forxiga, Xigduo, Ebymect); Boehringer Ingelheim International GmbH
(Jardiance; Synjardy)

Rapporteurs for the Article 20 referral: PRAC Rapporteur: Valerie Strassmann; PRAC Co-
rapporteur: Menno van der Elst

Individual products Rapporteur: Martina Weise, Co-Rapporteur: Kristina Dunder (Invokana),
Rapporteur: Martina Weise, Co-Rapporteur: Bjorg Bolstad (Vokanamet), Rapporteurs:
Kristina Dunder, Co-Rapporteur: Martina Weise (Edistride), Rapporteurs: Kristina Dunder,
Co-Rapporteur: Martina Weise (Forxiga), Rapporteur: Kristina Dunder, Co-Rapporteur:
Agnes Gyurasics (Xigduo), Rapporteur: Kristina Dunder, Co-Rapporteur: Agnes Gyurasics
(Ebymect), Rapporteur: Johann Lodewijk Hilleges, Co-Rapporteur: Bart Van der Schuuren
(Jardiance), Rapporteur: Johann Lodewijk Hilleges, Co-Rapporteur: Daniela Melchiorri
(Synjardy).

Scope: Opinion

Review of the benefit-risk balance of sodium-glucose co-transporter-2 (SGLT2) inhibitors
following notification by the European Commission of a referral under Article 20 of
Regulation (EC) No 726/2004, based on pharmacovigilance data

Action: For adoption

The PRAC adopted at its February 2017 meeting an opinion by consencus with the following
recommendation:

PRAC is warning that an increase in cases of lower limb amputation has been observed in
patients taking the type 2 diabetes medicine canagliflozin compared with those taking
placebo in two clinical trials, CANVAS and CANVAS-R. The studies, which are still ongoing,
involved patients at high risk of heart problems.

Patients with diabetes (especially those with poorly controlled diabetes and pre-existing
problems with the heart and blood vessels) are at increased risk of infection and ulcers
which can lead to amputations. The mechanism by which canagliflozin may increase the risk
of amputation is still unclear.
An increased risk has not been seen in studies with other medicines in the same class, dapagliflozin and empagliflozin. However, data available to date are limited and the risk may also apply to these other medicines.

10.2. **Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004**

10.2.1. **Desloratadine-containing products - desloratadine - EMEA/H/A-5(3)/1431**

Rapporteur: Koenrad Norga, Co-Rapporteur: Andrea Laslop,

Scope: List of Outstanding Issues/Opinion

Prescription status of desloratadine-containing products

Action: For adoption

10.3. **Procedure under Articles 5(2) and 10 of the Regulation (EC) No 726/2004**

10.4. **Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC**

10.4.1. **Paracomb 500mg/150mg film coated tablets - Paracetamol/Ibuprofen 500 mg/150 mg Paracetamol and Ibuprofen - EMEA/H/1447**

Vale Pharmaceutical Ltd

Rapporteur: Nithyanandan Nagercoil, Co-Rapporteur: Romaldas Maciulaitis

RMS: UK, CMS: AT, BE, DE, FR, HR, IE, LU, NL, PT, ES

Decentralised Procedure numbers: UK/H/6034-5/001/DC, UK/H/6176/001/DC

Scope: List of Outstanding Issues/Opinion

Disagreement regarding justification for a fixed dose combination, the demonstration of an additional benefit and of an acceptable safety profile

Action: For adoption

10.5. **Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC**

10.5.1. **Haldol and associated names - haloperidol - EMEA/H/A-30/1393**

Janssen-Cilag Group of companies and associated companies

Rapporteur: Martina Weise, Co-Rapporteur: Katarina Vučić,
Scope: Opinion

Harmonisation exercise for Haldol/Haldol Decanoate and associated names (haloperidol). Review triggered by the EC due to the need to harmonise the product information across all Member States, including the therapeutic indication, the posology, the contra-indications, special warnings and precautions for use and pregnancy and lactation and other sections.

**Action:** For adoption


### 10.5.2. Haldol decanoate and associated names – haloperidol - EMEA/H/A-30/1405

Janssen-Cilag Group of companies and associated companies

Rapporteur: Martina Weise, Co-Rapporteur: Katarina Vučić,

Scope: Opinion

Harmonisation exercise for Haldol/Haldol Decanoate and associated names (haloperidol). Review triggered by the EC due to the need to harmonise the product information across all Member States, including the therapeutic indication, the posology, the contra-indications, special warnings and precautions for use and pregnancy and lactation and other sections.

**Action:** For adoption


### 10.5.3. Saroten and associated names - amitriptyline - EMEA/H/A-30/1430

Lundbeck group of companies and associated companies, Bayer Vital and PNG Gerolymatos Medical

Rapporteur: Eleftheria Nikolaidi, Co-Rapporteur: Alar Irs,

Scope: Opinion

Harmonisation exercise for Saroten and associated names (amitriptyline). Review triggered by Greece due to the need to harmonise the product information across all Member States, including the therapeutic indication, the posology, the contra-indications, the adverse effects and the recommendations for use.

**Action:** For adoption


10.6.1. Symbioflor 2, Escherichia Coli bacteria (cells and autolysate) - EMEA/H/A-31/1441

Symbiopharm GmbH,
Rapporteur: Harald Enzmann, Co-rapporteur: Milena Stain;
Scope: Ad-hoc expert group report from meeting held on 13.01.2017
Article 31 triggered by the BfArM in Germany in March 2016 requesting the review of the benefit-risk balance for Symbioflor 2 and associated names following concerns that the effectiveness of the medicine(s) has not been adequately demonstrated.
Action: For information

10.6.2. Vancomycin containing products – (vancomycin) - EMEA/H/A-31/1440

Rapporteur: Concepcion Prieto-Yerro, Co-rapporteur: Alar Irs
Scope: List of Outstanding Issues
Action: For adoption
Review of the benefit-risk balance following notification by the Spanish Agency of Medicines and Medical Devices of a referral under Article 31 of Directive 2001/83/EC.


10.9. Disagreement between Member States on Type II variation – Arbitration procedure initiated by MAH under Article 6(13) (EC) No 1084/2003


10.11. Referral under Article 13 Disagreement between Member States on Type II variation – Arbitration procedure initiated by Member State under Article 13 (EC) No 1234/2008

10.11.1. Cardioxane - Dexrazoxane – EMEA/H/A-13/1453

Clinigen Group
RMS: FR, CMS: CZ, DE, ES, IT, NL, PL & UK
Decentralised Procedure numbers: FR/H/283/01/II/27G
Scope: Start of procedure and appointment of Rapporteurs

Article 13 triggered by the ANSM in France in January 2017 requesting the CHMP’s opinion whether the proposed lifting of the contraindication for a subset of anthracycline treated children is justified.

Action: For adoption

11. Pharmacovigilance issue

11.1. Early Notification System

February 2017 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

12. Inspections

12.1. GMP inspections

Disclosure of information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Disclosure of information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Disclosure of information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Disclosure of information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

Action: For information
13.2. **Innovation Task Force briefing meetings**

Disclosure of information related to briefing meetings taking place with applicants cannot be released at present time as deemed to contain commercially confidential information

Scope: ITF briefing meeting
Meeting date: 27 February 2017

**Action:** For adoption

Scope: ITF briefing meeting
Meeting date: 13 March 2017

**Action:** For adoption


13.4. **Nanomedicines activities**

14. **Organisational, regulatory and methodological matters**

14.1. **Mandate and organisation of the CHMP**

14.1.1. **CHMP meetings to be held in Valletta 28 February - 3 March 2017 under the Maltese Presidency of the Council of the European Union**

Scope: Information about the draft agenda topics of the upcoming Strategic Review and Learning meeting 28 February - 2 March 2017

**Action:** For discussion

Scope: Information about the draft agenda topics of the upcoming meeting on - Making Article 58 and other European Medicines Agency outputs more relevant for non-EU regulators to be held in Valetta 2 March - 3 March 2017

**Action:** For discussion

14.1.2. **Survey to committee members on the service provided by the Scientific Committees Service**

Scope: Findings of the survey to Committee Members

**Action:** For information
14.1.3. Report on Data-sharing initiative in Alzheimer’s disease

Scope: A joint SAWP/CNSWP initiative where EMA promoted a series of meetings with developers to critically appraise the methods used in recent Alzheimer’s disease programs and to share information in order to inform regulatory guidance.

Action: For information

14.1.4. CHMP and ORGAM meeting dates 2019-2021

Action: For adoption

14.1.5. Presentation on Experience of PAES

Scope: Review of experience on imposition of PAES.

Action: For information

14.1.6. ATMP guideline on safety and efficacy follow-up and risk management (EMA/CHMP/65416/2016)

Scope: Call for CHMP sponsors for the development of guidance and template

Action: For information

14.1.7. Overview on current activities in Africa

Scope: Summary on regional initiatives, WHO, Bill & Melinda Gates Foundation and other activities

Action: For information

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

Summary of recommendations and advice of PRAC meeting held on 06-09 February 2017

Action: For information

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for February 2017

Action: For adoption

14.2.2. Committee for Advanced Therapies (CAT)

CAT draft minutes of meeting held on 15-17 February 2017

Action: For information
14.2.3. Committee for Herbal Medicinal Products (HMPC)

Report from the HMPC meeting held on 30-31 January 2017

*Action:* For information

14.2.4. Paediatric Committee (PDCO)

PIPs reaching D30 at February 2017 PDCO

*Action:* For information

Report from the PDCO meeting held on 21-24 February 2017

*Action:* For information

Joint CHMP/PDCO session

Agenda for joint session

*Action:* For information

14.2.5. Committee for Orphan Medicinal Products (COMP)

Report from the COMP meeting held on 14-16 February 2017

*Action:* For information

14.2.6. Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh)

Report from the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) on the meeting held on 20-22 February 2017

*Action:* For information

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Scientific Advice Working Party (SAWP)

Report from the SAWP meeting held on 6-9 February 2017. Table of conclusions

*Action:* For information

Scientific advice letters: Disclosure of information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.
14.3.2. **Name Review Group (NRG)**

Table of Decisions of the NRG meeting held on 1 February 2017.

**Action:** For adoption

14.3.3. **Blood Products Working Party (BPWP)**

Vice-Chair: Karri Penttilä,


**Action:** For information

Nominations should be sent by 13 March 2017. Elections will take place at March 2017 CHMP.

14.3.4. **Biologics Working Party (BWP)**

Chair: Sol Ruiz


**Action:** For adoption

14.3.5. **Gastroenterology Drafting Group (GDG)**

Chair: Elmer Schabel

Scope: Election of a new Chairperson to Gastroenterology Drafting Group (GDG)

**Action:** For adoption

14.3.6. **Pharmacogenomics Working Party (PGWP)**

Chair: Krishna Prasad/Markus Paulmichl,

Nomination of two new additional experts: Sir Munir Pirmohamed (UK) and Wilko Weichert (DE)

**Action:** For adoption

14.3.7. **Vaccines Working Party (VWP)**

Chair: Mair Powell

Nomination of new additional experts: Daniel Brasseur (BE)

**Action:** For adoption
14.3.8. Rheumatology/Immunology Working Party (RIWP)

Chair: Jan Mueller-Berghaus,

Review of the composition of drafting groups and temporary working parties in view of goals to be achieved in 2017.

**Action:** For discussion

14.3.9. Oncology Working Party (ONCWP)

Chair: Pierre Demolis/Paolo Foggi,

Concept paper on a proposal to replace the reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products with a new PRO guideline.

**Action:** For adoption for public consultation

14.3.10. Antimicrobial Advice ad hoc Expert Group (AMEG)

Scope: Extension of the AMEG task to update the categorisation of antimicrobials and the proposed early hazard characterisation.

**Action:** For adoption

14.3.11. Quality Working Party (QWP)

Chair: Jean-Louis Robert

Scope: Incompatibility of meropenem and ciprofloxacin leading to possible precipitation when co-administered intravenously – QWP responses to PRAC questions

**Action:** For adoption

Scope: ICH Q3D implementation strategy

**Action:** For information


Chair: Jan Willem Van der Laan / Sonja Beken,

Scope: Nomination of John Jensen (DKMA) as new member of the ERA Drafting Group.

**Action:** For adoption
14.4. **Cooperation within the EU regulatory network**

14.5. **Cooperation with International Regulators**

14.5.1. EMA/FDA strategic document on Gaucher disease

**Action:** For information

14.6. **Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee**

14.7. **CHMP work plan**

14.7.1. CHMP 2017 Work Plan

**Action:** For adoption

14.8. **Planning and reporting**

14.9. **Others**

15. **Any other business**

15.1. **AOB topic**

15.1.1. Operation and Relocation Preparedness - Workstream 2 - Operational Preparedness

**Action:** For discussion
16. Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations (section 2)

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications (section 3)

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an opinion at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:

The assessment of an application for a new medicine takes up to 210 ‘active’ days. This active evaluation time is interrupted by at least one ‘clock-stop’ during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (Day 180 List of outstanding issues) and 3.3 (Day 120 list of questions).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, update on ongoing new applications for centralised procedures.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, products in the decision making phase.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 (section 4)

Extensions of marketing authorisations are applications for the change or addition of new strengths,
formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

**Type II variations - Extension of indication procedures (section 5)**

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

**Ancillary medicinal substances in medical devices (section 6)**

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

**Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 3.5)**

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

**Re-examination procedures (section 5.3)**

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

**Withdrawal of application (section 3.7)**

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

**Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) (section 7)**

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

**Pre-submission issues (section 8)**

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

**Post-authorisation issues (section 9)**

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

**Referral procedures (section 10)**

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a
particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

**Pharmacovigilance issues (section 11)**

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA’s committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

**Inspections Issues (section 12)**

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

**Innovation task force (section 13)**

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

**Scientific advice working party (SAWP) (section 14.3.1)**

This section refers to the monthly report from the CHMP’s Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

**Satellite groups / other committees (section 14.2)**

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmacovigilance Risk Assessment Committee (PRAC).

**Invented name issues (section 14.3)**

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group’s main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

More detailed information on the above terms can be found on the EMA website: [www.ema.europa.eu/](http://www.ema.europa.eu/)
Annex to February 2017 CHMP Agenda

PRE SUBMISSION AND POST AUTHORISATIONS ISSUES

A. PRE SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

B.2.2. Renewals of Marketing Authorisations for unlimited validity

B.2.3. Renewals of Conditional Marketing Authorisations

B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

B.4. EPARs / WPARs

B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

B.5.3. CHMP-PRAC assessed procedures

B.5.4. PRAC assessed procedures

B.5.5. CHMP-CAT assessed procedures

B.5.6. CHMP-PRAC-CAT assessed procedures

B.5.7. PRAC assessed ATMP procedures

B.5.8. Unclassified procedures and worksharing procedures of type I variations

B.5.9. Information on withdrawn type II variation / WS procedure

B.5.10. Information on type II variation / WS procedure with revised timetable

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

B.6.1. Start of procedure for New Applications: timetables for information

B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008: timetables for information

B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information

B.6.4. Annual Re-assessments: timetables for adoption

B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

B.6.6. VARIATIONS – START OF THE PROCEDURE
B.6.7. Type II Variations scope of the Variations: Extension of indication ......................... 48
B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects .................................. 52
B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects .................. 54
B.6.10. CHMP-PRAC assessed procedures ................................................................. 57
B.6.11. PRAC assessed procedures .............................................................................. 61
B.6.12. CHMP-CAT assessed procedures ..................................................................... 63
B.6.13. CHMP-PRAC-CAT assessed procedures .............................................................. 63
B.6.14. PRAC assessed ATMP procedures ................................................................... 63
B.6.15. Unclassified procedures and worksharing procedures of type I variations ............. 63
B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY .............................. 64
B.7.1. Line listing for Variation Type I and Variation Type II (MMD only) post authorisation procedures from the beginning of the year ................................................................. 64
B.7.2. Line listing overview of all applications under the centralised procedure (MMD only). line listing - products - authorised, under evaluation, suspended.xls .................................. 64
B.7.3. Opinion on Marketing Authorisation transfer (MMD only) .................................... 64
B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only). ........................................................................................................... 64
B.7.6. Notifications of Type I Variations (MMD only). .................................................. 64
C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled) ................................................. 64
D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed) .................................................................................................................. 64
E. Annex E - EMEA CERTIFICATION OF PLASMA MASTER FILES .................. 64
E.1. PMF Certification Dossiers: ................................................................................... 65
E.1.1. Annual Update ................................................................................................. 65
E.1.2. Variations: ...................................................................................................... 65
E.1.3. Initial PMF Certification: .................................................................................. 65
E.2. Time Tables – starting & ongoing procedures: For information ................................ 65
F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver ................. 65
F.2. Request for scientific opinion on justification of exceptional circumstance and for imperative grounds of public health ................................................................. 65
G. ANNEX G .............................................................................................................. 65
G.1. Final Scientific Advice (Reports and Scientific Advice letters): ............................... 65
G.2. Ongoing procedures ........................................................................................... 65
G.3. PRIME ............................................................................................................... 65
G.3.1. List of procedures concluding at 20-23 February 2017 CHMP plenary: ............... 66
G.3.2. List of procedures starting in Month 20xx for Month 20xx CHMP adoption of outcomes .................................................................................................................... 66
H. ANNEX H - Product Shared Mailboxes – e-mail address..........................66

A. PRE SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for February 2017: For adoption

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for February 2017: For adoption

A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Disclosure of information related to pre-submission of initial applications cannot be released at present time as these contain commercially confidential information.

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

**Glybera - alipogene tiparvovec** - EMEA/H/C/002145/S/0057, Orphan, ATMP
MAH: uniQure biopharma B.V., Rapporteur: Christiane Niederlaender, PRAC Rapporteur: Julie Williams
Request for Supplementary Information adopted on 20.01.2017.

**Increlex - mecasermin** - EMEA/H/C/000704/S/0041, Orphan
MAH: Ipsen Pharma, Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kirsti Villikka

**Lojuxta - lomitapide** - EMEA/H/C/002578/S/0023
MAH: Aegerion Pharmaceuticals Limited, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst
Request for Supplementary Information adopted on 10.11.2016.

**Obizur - susoctocog alfa** - EMEA/H/C/002792/S/0006
B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

**Bretaris Genuair - aclidinium -**  
EMEA/H/C/002706/R/0031  
MAH: AstraZeneca AB, Duplicate, Duplicate of Eklira Genuair, Rapporteur: Nithyanandan Nagercoil, Co-Rapporteur: Piotr Fiedor, PRAC Rapporteur: Julie Williams

**Kalydeco - ivacaftor -**  
EMEA/H/C/002494/R/0052, Orphan  

**Siklos - hydroxycarbamide -**  
EMEA/H/C/000689/R/0030, Orphan  

B.2.2. Renewals of Marketing Authorisations for unlimited validity

**alli - orlistat -** EMEA/H/C/000854/R/0054  

**Atriance - nelarabine -**  
EMEA/H/C/000752/R/0037, Orphan  
MAH: Novartis Europharm Ltd, Rapporteur: Sinan B. Sarac, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Torbjorn Callreus

**Eklira Genuair - aclidinium -**  
EMEA/H/C/002211/R/0031  
MAH: AstraZeneca AB, Rapporteur: Nithyanandan Nagercoil, Co-Rapporteur: Piotr Fiedor, PRAC Rapporteur: Julie Williams
Flebogamma DIF - human normal immunoglobulin -
EMEA/H/C/000781/R/0048

Increlex - mecasermin -
EMEA/H/C/000704/R/0042, Orphan

Jakavi - ruxolitinib -
EMEA/H/C/002464/R/0032

Pergoveris - follitropin alfa / lutropin alfa -
EMEA/H/C/000714/R/0050

Rasilez - aliskiren -
EMEA/H/C/000780/R/0112
MAH: Novartis Europharm Ltd, Rapporteur: Daniela Melchiorri, Co-Rapporteur: Melinda Sobor, PRAC Rapporteur: Carmela Macchiarulo

Zinforo - ceftaroline fosamil -
EMEA/H/C/002252/R/0031
MAH: AstraZeneca AB, Rapporteur: Greg Markey, Co-Rapporteur: Alar Irs, PRAC Rapporteur: Julie Williams

Zoledronic acid medac - zoledronic acid -
EMEA/H/C/002359/R/0018
MAH: medac Gesellschaft fur klinische Spezialpraparate mbH, Generic, Generic of Zometa, Rapporteur: Alar Irs, PRAC Rapporteur: Doris Stenver

B.2.3. Renewals of Conditional Marketing Authorisations

Darzalex - daratumumab -
EMEA/H/C/004077/R/0003, Orphan
MAH: Janssen-Cilag International NV,  
Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

**Pandemic influenza vaccine H5N1**  
MedImmune - pandemic influenza vaccine (H5N1) (live attenuated, nasal) -  
EMEA/H/C/003963/R/0003  
MAH: MedImmune LLC, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Jan Neuhauser

### B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

#### Signal detection

PRAC recommendations on signals adopted at the PRAC meeting held on on 06-09 February 2017:

- **Opdivo (EMEA/H/C/003985)**  
  (Nivolumab), MAH: Bristol-Myers Squibb Pharma EEIG, Rapporteur: Aranzazu Sancho-Lopez, Co-Rapporteur: Paula Boudewina van Hennik, EPL: Silvy Da Rocha Dias,  
  Signal of pemphigoid: **For adoption**

PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its February 2017 meeting:

- **EMEA/H/C/PSUSA/00002665/201607**  
  (rotavirus vaccine monovalent (live, oral))  
  CAPS:  

- **EMEA/H/C/PSUSA/00010035/201607**  
  (ingenol mebutate)  
  CAPS:  

- **EMEA/H/C/PSUSA/00010404/201607**  
  (atazanavir / cobicistat)  
  CAPS:  
  **EVOTAZ** (EMEA/H/C/003904) (atazanavir / cobicistat), MAH: Bristol-Myers Squibb Pharma
EEIG, Rapporteur: Bruno Sepodes, PRAC

**EMEA/H/C/PSUSA/00010447/201607**
(brivaracetam)
CAPS:
**Briviact** (EMEA/H/C/003898) (brivaracetam),

---

**B.4. EPARs / WPARs**

**AMGEVITA - adalimumab -**
**EMEA/H/C/004212**
Applicant: Amgen Europe B.V., treatment of rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, Crohn’s disease, paediatric Crohn’s disease and Ulcerative colitis,
Similar biological application (Article 10(4) of Directive No 2001/83/EC)

**Daptomycin Hospira - daptomycin -**
**EMEA/H/C/004310**
Applicant: Hospira UK Limited, treatment of complicated skin and soft-tissue infections,
Generic, Generic of Cubicin, Generic application (Article 10(1) of Directive No 2001/83/EC)

**Jylamvo - methotrexate -**
**EMEA/H/C/003756**
Applicant: Therakind Limited, treatment of rheumatological and dermatological diseases,
Hybrid application (Article 10(3) of Directive No 2001/83/EC)

**LifeGlobal Media - human serum albumin -**
**EMEA/H/D/004287**
Applicant: BSI Group, washing, handling, manipulation and/or cryopreservation of gametes and embryos for assisted human reproductive technology vitamins which may be present in trace quantities and acts as a carrier of these substances to support growth and maintenance of gametes and/or embryos. Scavenges embryotoxic components generated prevents adsorption to the container of various
amino acids and vitamins, acts as a carrier of these substances to support growth and maintenance of gametes and/or embryos, Scavenges embryotoxic components generated during embryo's metabolism in vitro, Ancillary medicinal substance/blood derivative substance (Article 1(4)/1(4a) of both Directives No 93/42/EEC and 90/385/EEC)

Rolufta - umeclidinium -  EMEA/H/C/004654
Applicant: GlaxoSmithKline Trading Services Limited, treatment of chronic obstructive pulmonary disease (COPD), Informed consent application (Article 10c of Directive No 2001/83/EC)

SOLYMBIC - adalimumab -  EMEA/H/C/004373
Applicant: Amgen Europe B.V., treatment of rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, Crohn's disease, paediatric Crohn's disease and Ulcerative colitis, Duplicate, Duplicate of AMGEVITA, Similar biological application (Article 10(4) of Directive No 2001/83/EC)

Tadalafil Lilly - tadalafil -  EMEA/H/C/004666

Xeljanz - tofacitinib -  EMEA/H/C/004214
Applicant: Pfizer Limited, treatment of active rheumatoid arthritis, New active substance (Article 8(3) of Directive No 2001/83/EC)

Yargesa - miglustat -  EMEA/H/C/004016
Applicant: JensonR+ Limited, treatment of Gaucher disease, Generic, Generic of Zavesca, Generic application (Article 10(1) of Directive No 2001/83/EC)

B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Disclosure of scopes related to Chemistry, Manufacturing, and Controls cannot be released at
present time as these contain commercially confidential information.

### B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

<table>
<thead>
<tr>
<th>Product</th>
<th>Reference</th>
<th>MAH</th>
<th>Rapporteur</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adcetris - brentuximab vedotin</td>
<td>EMEA/H/C/002455/II/0041/G, Orphan</td>
<td>Takeda Pharma A/S,</td>
<td>Paula Boudewina van Hennik</td>
</tr>
<tr>
<td>Advate - octocog alfa</td>
<td>EMEA/H/C/000520/II/0082/G</td>
<td>Baxter AG,</td>
<td>Jan Mueller-Berghaus</td>
</tr>
<tr>
<td>Bemfola - follitropin alfa</td>
<td>EMEA/H/C/002615/II/0011</td>
<td>Gedeon Richter Plc.,</td>
<td>Paula Boudewina van Hennik</td>
</tr>
<tr>
<td>Cerezyme - imiglucerase</td>
<td>EMEA/H/C/000157/II/0099/G</td>
<td>Genzyme Europe BV,</td>
<td>Johann Lodewijk Hillege</td>
</tr>
<tr>
<td>Cimzia - certolizumab pegol</td>
<td>EMEA/H/C/001037/II/0058/G</td>
<td>UCB Pharma S.A.,</td>
<td>Kristina Dunder</td>
</tr>
<tr>
<td>Colobreathe - colistimethate sodium</td>
<td>EMEA/H/C/001225/II/0023</td>
<td>Teva B.V.,</td>
<td>Nithyanandan Nagercoil</td>
</tr>
<tr>
<td>Cosentyx - secukinumab</td>
<td>EMEA/H/C/003729/II/0017</td>
<td>Novartis Europharm Ltd,</td>
<td>Tuomo Lapveteläinen</td>
</tr>
<tr>
<td>Darzalex - daratumumab</td>
<td>EMEA/H/C/004077/II/0004, Orphan</td>
<td>Janssen-Cilag International NV,</td>
<td>Sinan B. Sarac</td>
</tr>
<tr>
<td>Darzalex - daratumumab</td>
<td>EMEA/H/C/004077/II/0005/G, Orphan</td>
<td>Janssen-Cilag International NV,</td>
<td>Sinan B. Sarac</td>
</tr>
<tr>
<td>Emtricitabine/Tenofovir disoproxil Zentiva</td>
<td>- emtricitabine / tenofovir disoproxil -</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EMEA/H/C/004137/II/0001</td>
<td>MAH: Zentiva k.s., Generic, Generic of Truvada, Rapporteur: Alar Irs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------</td>
<td>---------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HBVAXPRO - hepatitis B vaccine (rDNA) -</strong> EMEA/H/C/000373/II/0055</td>
<td>Positive Opinion adopted by consensus on 02.02.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation. MAH: Sanofi Pasteur MSD SAS, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 02.02.2017.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Herceptin - trastuzumab -</strong> EMEA/H/C/000278/II/0127/G</td>
<td>Weekly start timetable. The Committee adopted a Request for Supplementary information together with a specific timetable. MAH: Roche Registration Limited, Rapporteur: Jan Mueller-Berghaus</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hizentra - human normal immunoglobulin -</strong> EMEA/H/C/002127/II/0074/G</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Increlex - mecasermin -</strong> EMEA/H/C/000704/II/0046/G, Orphan</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Inhixa - enoxaparin sodium -</strong> EMEA/H/C/004264/II/0004/G</td>
<td>Weekly start timetable. MAH: Techdow Europe AB, Duplicate, Duplicate of Thorinane, Rapporteur: Andrea Laslop</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Inhixa - enoxaparin sodium -</strong></td>
<td>Weekly start timetable.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
EMEA/H/C/004264/II/0005/G
MAH: Techdow Europe AB, Duplicate, Duplicate of Thorinane, Rapporteur: Andrea Laslop

Kanuma - sebelipase alfa -  
EMEA/H/C/004004/II/0006/G, Orphan  
MAH: Alexion Europe SAS, Rapporteur: Bart Van der Schueren  
Request for Supplementary Information adopted on 10.11.2016.

Lantus - insulin glargine -  
EMEA/H/C/000284/II/0107/G  
MAH: Sanofi-aventis Deutschland GmbH, Rapporteur: Johann Lodewijk Hillege  
Weekly start timetable.

Nimenrix - meningococcal group A, C, W135 and Y conjugate vaccine -  
EMEA/H/C/002226/II/0062  
MAH: Pfizer Limited, Rapporteur: Greg Markey  

Onivyde - irinotecan hydrochloride trihydrate - EMEA/H/C/004125/II/0002, Orphan  
MAH: Baxalta Innovations GmbH, Rapporteur: Filip Josephson  
Positive Opinion adopted by consensus on 09.02.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

OPDIVO - nivolumab -  
EMEA/H/C/003985/II/0022/G  
MAH: Bristol-Myers Squibb Pharma EEIG, Rapporteur: Aranzazu Sancho-Lopez  

Orencia - abatacept -  
EMEA/H/C/000701/II/0106/G  
MAH: Bristol-Myers Squibb Pharma EEIG, Rapporteur: Outi Mäki-Ikola  
Request for Supplementary Information adopted on 02.02.2017.

Pheburane - sodium phenylbutyrate -  
EMEA/H/C/002500/II/0014  
MAH: Lucane Pharma, Rapporteur: David Lyons  
Opinion adopted on 02.02.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Prevenar 13 - pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) -  
EMEA/H/C/001104/II/0147/G  
Positive Opinion adopted by consensus on 02.02.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<table>
<thead>
<tr>
<th>Product Name</th>
<th>RA</th>
<th>MAH</th>
<th>Rapporteur</th>
<th>CHMP Decision</th>
<th>CHMP Members' Agreement</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rivastigmine 1A Pharma - rivastigmine</strong>&lt;br&gt;EMEA/H/C/001181/II/0022/G</td>
<td>MAH: 1 A Pharma GmbH, Informed Consent of Exelon, Rapporteur: Alexandre Moreau</td>
<td>Opinion adopted on 09.02.2017.</td>
<td>Positive Opinion adopted by consensus on 09.02.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Silapo - epoetin zeta</strong>&lt;br&gt;EMEA/H/C/000760/II/0044</td>
<td>MAH: STADA Arzneimittel AG, Rapporteur: Martina Weise</td>
<td>Weekly start timetable.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tenofovir disoproxil Zentiva - tenofovir disoproxil</strong>&lt;br&gt;EMEA/H/C/004120/II/0001</td>
<td>MAH: Zentiva k.s., Generic, Generic of Viread, Rapporteur: John Joseph Borg</td>
<td>Weekly start timetable.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Request for Supplementary Information adopted on 24.11.2016.

**Velphoro - mixture of polynuclear iron(III)-oxyhydroxide, sucrose and starches - EMEA/H/C/002705/II/0009/G**
MAH: Vifor Fresenius Medical Care Renal Pharma France, Rapporteur: Johann Lodewijk Hillege

**WS0954**
Filgrastim Hexal-
EMEA/H/C/000918/WS0954/0033
Zarzio-EMEA/H/C/000917/WS0954/0034
MAH: SANDOZ GmbH, Lead Rapporteur: Greg Markey
Request for Supplementary Information adopted on 10.11.2016.

**WS1043/G**
Helixate NexGen-
EMEA/H/C/000276/WS1043/0182/G
KOGENATE Bayer-
EMEA/H/C/000275/WS1043/0189/G
MAH: Bayer Pharma AG, Lead Rapporteur: Jan Mueller-Berghaus
Request for Supplementary Information adopted on 24.11.2016.

**WS1068/G**
Infanrix hexa-
EMEA/H/C/000296/WS1068/0216/G
MAH: GSK Biologicals SA, Lead Rapporteur: Bart Van der Schueren

**B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects**

**Azarga - brinzolamide / timolol - EMEA/H/C/000960/II/0034**
MAH: Alcon Laboratories (UK) Ltd, Rapporteur: Hanne Lomholt Larsen, “Update of sections 4.2, 4.4, 4.6 and 4.8 of the SmPC following a review of the safety profile taking into consideration data from clinical studies and post-marketing experience. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and Package Leaflet and to update the contact details for the local representative in Spain in the Package Leaflet.”
Request for Supplementary Information adopted on 24.11.2016.

Weekly start timetable.

Weekly start timetable.

Positive Opinion adopted by consensus on 02.02.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Weekly start timetable.

Weekly start timetable. The Committee adopted a Request for Supplementary information together with a specific timetable.
**BeneFIX - nonacog alfa -**
**EMEA/H/C/000139/II/0141**
MAH: Pfizer Limited, Rapporteur: Jan Mueller-Berghaus, "Update of section 5.2 of the SmPC in order to update the information based on PK data from study B1821048. This study reported PK from an extended collection time beyond the 72 hours previously used in all other BeneFIX studies, to 96 hours, after BeneFIX administration."

**Cerdelga - eliglustat -**
**EMEA/H/C/003724/II/0008, Orphan**
MAH: Genzyme Europe BV, Rapporteur: Johann Lodewijk Hillege, "Update of SmPC section 5.1 to include 2, 3 and 4 years composite stability endpoint data based on the final results of the ENCORE study."

**Cervarix - human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed) - EMEA/H/C/000721/II/0075**
MAH: GSK Biologicals SA, Rapporteur: Bart Van der Schueren, "Variations that do not affect the PI (C.I.13)
Submission of study HPV-015 (MEA 083): A phase III, double-blind, randomized, controlled study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals' HPV_16/18 L1/AS04 vaccine administered intramuscularly according to a three-dose schedule (0, 1, 6 month) in healthy adult female subjects aged 26 years and above. At final analysis (M84) of study HPV-015, a new medical review of new onset of adverse events (NOADs) collected up to M48 was performed at M84. An additional analysis on potential immune mediated diseases (pIMDs) and pregnancy outcomes collected at M48 was also done at M84. No changes in the PI are proposed"

**Cervarix - human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed) - EMEA/H/C/000721/II/0080**
for study HPV-060. Study HPV-060 is an extension of the study HPV-014 (EXT 014 Y5-10). Study HPV-014 with 4 years post-vaccination data was submitted as a commitment in November 2009 (EMEA/H/C/721/FU2 20.5)
The purpose of this variation is to fulfil the Post- Authorization Measure (PAM) (MEA-082) with the long term follow up (10 years post-vaccination) data from study HPV-060. GlaxoSmithKline Biologicals (GSK Biologicals) considers that there is no need to change the SmPC at this stage."

**Cimzia - certolizumab pegol -**
**EMEA/H/C/001037/II/0057/G**
MAH: UCB Pharma S.A., Rapporteur: Kristina Dunder
- C.I.4 (Type II) - amend the Product Information (PI) to add the Dose-dispenser Cartridge presentations."

**Descovy - emtricitabine / tenofovir alafenamide - EMEA/H/C/004094/II/0013**
MAH: Gilead Sciences International Ltd, Rapporteur: Robert James Hemmings,
"Submission of 96 week data from Study GS-US-311-1089 in order to support an update of the virological outcomes and measures of bone mineral density in Section 5.1 of the Summary of Product Characteristics (SmPC)."

**Dynastat - parecoxib -**
**EMEA/H/C/000381/II/0068/G**
MAH: Pfizer Limited, Duplicate, Duplicate of Xapit, Rapporteur: David Lyons, "C.I.4 - Update of section 4.4 of the SmPC in order to update the safety information related to cardiovascular risk information. C.I.4 - Update of section 4.4 of the SmPC in order to update the safety information related to alcohol use and gastrointestinal (GI) risk. C.I.4 - Update of section 4.6 of the SmPC in order to update the safety information related to oligohydramnios if the product is used during second or third trimester of pregnancy. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of Weekly start timetable.
local representatives in the Package Leaflet, to bring the PI in line with the latest QRD template version 10.0 and to correct some mistakes.”

**Fycompa - perampanel -**  
**EMEA/H/C/002434/II/0034/G**  
MAH: Eisai Europe Ltd., Rapporteur: Robert James Hemmings, “Update of sections 4.5 and 5.1 of the SmPC in order to add information on the conversion of patients to Fycompa monotherapy (E2007-G000-504, hereby Study 504) and to include the effect of withdrawal of concomitant enzyme-inducing antiepileptic drugs (EIAEDs) on plasma concentrations of perampanel (A supportive analysis, CPMS-E2007-0013R). In addition, the Marketing authorisation holder (MAH) took the opportunity to bring the PI in line with the latest QRD template version 10.” Request for Supplementary Information adopted on 15.12.2016.

**Giotrif - afatinib -**  
**EMEA/H/C/002280/II/0022**  
MAH: Boehringer Ingelheim International GmbH, Rapporteur: Filip Josephson, “Update of section 5.1 of the SmPC in order to update the information about the major mechanism of acquired resistance to afatinib. In addition, the Marketing authorisation holder (MAH) took the opportunity to add the side effects ‘itching’ and ‘dry skin’ with frequency very common to the package leaflet to bring it in line with the SmPC.”

**GONAL-f - follitropin alfa -**  
**EMEA/H/C/000071/II/0136**  
MAH: Merck Serono Europe Limited, Rapporteur: Nithyanandan Nagercoil, "Update of the SmPC sections 4.4 and 4.8 to revise the frequency of thromboembolic events from 'very rare' to 'rare'. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is brought in line with the latest QRD template version 10.0.” Request for Supplementary Information adopted on 02.02.2017.

**Harvoni - ledipasvir / sofosbuvir -**  
**EMEA/H/C/003850/II/0035**  
MAH: Gilead Sciences International Ltd,
Rapporteur: Filip Josephson, "Update of sections 4.8, 5.1 and 5.2 of the SmPC in order to add emerging clinical data available from studies SOLAR-1 and SOLAR-2.”
Request for Supplementary Information adopted on 10.11.2016.

**Harvoni - ledipasvir / sofosbuvir -**
**EMEA/H/C/003850/II/0046**  
MAH: Gilead Sciences International Ltd,  
Rapporteur: Filip Josephson, “Submission of the final clinical study report of the study GS-US-337-1118: an Open-Label, Multicenter Study To Evaluate The Efficacy And Safety Of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin For 12 or 24 Weeks In Chronic Genotype 1 HCV Infected Subjects Who Participated In A Prior Gilead-Sponsored HCV Treatment Study”

**Iressa - gefitinib -**
**EMEA/H/C/001016/II/0026**  
MAH: AstraZeneca AB, Rapporteur: Filip Josephson, “Submission of final study report for IMPRESS study (D791LC00001) and discussion to address one of the 'PRAC Recommendations as per procedure regarding the gefitinib Periodic Safety Update Report (PSUR: EMA/PRAC/4284/2016). No Changes in the PI and in the RMP are proposed”  
Request for Supplementary Information adopted on 13.10.2016.

**Jardiance - empagliflozin -**
**EMEA/H/C/002677/II/0025**  
MAH: Boehringer Ingelheim International GmbH, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Dolores Montero Corominas, “Submission of the final results for a non-interventional study 1245.122 exploring the characteristics of patients initiating empagliflozin or other noninsulin glucose lowering drugs in the United Kingdom in order to fulfil MEA 009. The RMP (version 11.0) is updated accordingly.”

**Keytruda - pembrolizumab -**
**EMEA/H/C/003820/II/0013**  
MAH: Merck Sharp & Dohme Limited, Rapporteur: Daniela Melchiorri, “Update of section 4.4 of the SmPC to amend existing warnings on immune-related adverse reactions. In addition, the MAH took the opportunity to Positive Opinion adopted by consensus on 02.02.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
revise the instructions for handling and storage after reconstitution in SmPC sections 6.3 and 6.6 for increased clarity. The Package Leaflet has been updated accordingly.”

Mimpara - cinacalcet -
EMEA/H/C/000570/II/0056
MAH: Amgen Europe B.V., Rapporteur: Kristina Dunder, “Submission of the final report for Study 20090686, a study designed to determine the efficacy of cinacalcet compared with vitamin D therapy for management of secondary HPT (hyperparathyroidism) in haemodialysis subjects.
This variation fulfills LEG 031.”

Mysimba - naltrexone hydrochloride / bupropion hydrochloride -
EMEA/H/C/003687/II/0010

Mysimba - naltrexone hydrochloride / bupropion hydrochloride -
EMEA/H/C/003687/II/0011
MAH: Orexigen Therapeutics Ireland Limited, Rapporteur: Hanne Lomholt Larsen, “Submission of study report NaltrexBupro-4001 - A Multicenter, Randomized, Double-blind, Placebo controlled, Phase 4 Study to Assess the Effect of Naltrexone Hydrochloride and Bupropropion Hydrochloride Extended Release Combination on the Occurrence of Major Adverse Cardiovascular Events in Overweight and Obese Subjects with Cardiovascular Disease. The product information remains unchanged.”

Noxafil - posaconazole -
EMEA/H/C/000610/II/0048
<table>
<thead>
<tr>
<th>Product</th>
<th>EMEA/H/C/</th>
<th>MAH</th>
<th>Rapporteur</th>
<th>Request for Supplementary Information adopted on</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Praluent - alirocumab</td>
<td>EMEA/H/C/003882/II/0018</td>
<td>sanofi-aventis groupe, Rapporteur: Johann Lodewijk Hillege</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

4.4 and 4.5 of the SmPC in order to strengthen the current warning on interaction of posaconazole with vincristine. The Package Leaflet is updated accordingly.
In addition, the Marketing authorisation holder (MAH) took the opportunity to bring the PI in line with the latest QRD template version 10.”

Nulojix - belatacept -
EMEA/H/C/002098/II/0038
MAH: Bristol-Myers Squibb Pharma EEIG,
Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga, "Update of sections 4.8 and 5.1 of the SmPC in order to update the safety information following the completion of the IM103-008 and IM103_027post-authorization efficacy studies.
The Package Leaflet and and Risk Management Plan (Version 12) are updated accordingly.”
Request for Supplementary Information adopted on 15.09.2016.

OPDIVO - nivolumab -
EMEA/H/C/003985/II/0023
MAH: Bristol-Myers Squibb Pharma EEIG,
Rapporteur: Aranzazu Sancho-Lopez, "Update of sections 4.8 and 5.1 of the SmPC in order to update the safety and pharmacological information with the 24 months data from the completed NSCLC studies CA209017 and CA209057.”
Request for Supplementary Information adopted on 19.01.2017.

Pradaxa - dabigatran etexilate -
EMEA/H/C/000829/II/0097
Request for Supplementary Information adopted on 01.12.2016.

Praluent - alirocumab -
EMEA/H/C/003882/II/0018
MAH: sanofi-aventis groupe, Rapporteur: Johann Lodewijk Hillege, "Submission of study PDY13670 a Phase 1 study of the effects of
subcutaneous doses of alirocumab on lipid and lipoprotein metabolism in adults with mildly elevated LDL-cholesterol.”

**Prevenar 13 - pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)** -
**EMEA/H/C/001104/II/0145**
MAH: Pfizer Limited, Rapporteur: Kristina Dunder, "Update of the SmPC section 5.1 with information on Prevenar 13 effects on invasive pneumococcal disease, antimicrobial resistance and otitis media caused by nontypeable H. influenzae. Editorial changes have also been proposed throughout the SmPC.”

**Prevenar 13 - pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)** -
**EMEA/H/C/001104/II/0149**
MAH: Pfizer Limited, Rapporteur: Kristina Dunder, "Submission of the final clinical study report (CSR) of study B1851018, a Phase 4 study evaluating the impact of 13vPnC in reducing AOM and NP colonisation caused by S pneumoniae in healthy children, in accordance with the Pharmacovigilance plan outlined in the EU RMP (version 11.0).”

**Rapamune - sirolimus** -
**EMEA/H/C/000273/II/0163/G**
MAH: Pfizer Limited, Rapporteur: Kristina Dunder, "Update of section 4.4 of the SmPC to update the current warning on angioedema to include a possible dose-dependent effect between sirolimus and angioedema based on post-marketing data. Update of section 4.8 of the SmPC to include neuroendocrine carcinoma of the skin and malignant carcinoma as new ADRs and to include squamous cell carcinoma of the skin and basal cell carcinoma as part of the ADR 'skin cancer' based on post-marketing data. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to combine the 0.5 mg, 1 mg and 2 mg tablets SmPC, to fully detail all components of the Rapamune printing ink in section 6.1 of the SmPC and in the Package Leaflet, to align the wording in section 4 of the Package Leaflet with Weekly start timetable.
section 4.8 of the SmPC regarding Clostridium difficile, to update the list of local representatives for the Czech republic, Norway and Sweden in the Package Leaflet and to bring the PI in line with the latest QRD template version 10.”
Request for Supplementary Information adopted on 01.12.2016.

Revestive - teduglutide -
EMEA/H/C/002345/II/0037, Orphan
MAH: Shire Pharmaceuticals Ireland Ltd, Rapporteur: Sinan B. Sarac, “Update of section 4.2 of the SmPC in order to amend the recommendation that treatment effect should be evaluated after 12 months (instead of the current recommended 6 months) based on literature references.”

Simponi - golimumab -
EMEA/H/C/000992/II/0072
MAH: Janssen Biologics B.V., Rapporteur: Kristina Dunder, “Update of section 4.4 of the SmPC in order to include reports of Merkel cell carcinoma in patients treated with TNF blocking agents including Simponi. In addition the frequency of this ADR has been reclassified from "not known" to "rare" in section 4.8 of the SmPC. The Package Leaflet is updated accordingly. Finally the Marketing Authorisation Holder (MAH) took the opportunity to make a small correction in section 5.1 of the SmPC.”

Thalidomide Celgene - thalidomide -
EMEA/H/C/000823/II/0050, Orphan
MAH: Celgene Europe Limited, Rapporteur: Alexandre Moreau, “Submission of a final clinical study report for Study CC-2001-CP-001 together with the population pharmacokinetics (PK) meta-analysis CC-2001-MPK-001 and bioanalytical report CC-2001-CP-001-BA undertaken to evaluate thalidomide PK in multiple myeloma subjects in order to fulfil legally binding measure LEG 027.3.”

Vimpat - lacosamide -
EMEA/H/C/000863/II/0066/G
MAH: UCB Pharma S.A., Rapporteur: Filip Josephson, “Update of section 4.2 of the SmPC in order to update the safety information regarding the use of lacosamide in patients with hepatic impairment, section 4.8 to add a new
adverse drug reaction (hepatic enzyme increased (> 2x ULN)) and section 4.9 regarding lacosamide overdose based on postmarketing reports. The Package Leaflet is updated accordingly.

In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet and to make minor editorial change in the SmPC.” Request for Supplementary Information adopted on 15.12.2016.

**Zaltrap - aflibercept -**
EMEA/H/C/002532/II/0035

MAH: Sanofi-Aventis Groupe, Rapporteur: Filip Josephson, “Update the Product Information (SmPC, section 5.1 Pharmacodynamic properties) to reflect the results of the biomarker programme encompassing the EFC10262, EFC10668 and EFC11338 studies in order to fulfil the Annex II condition of Zaltrap, aflibercept 25 mg/ml, Concentrate for solution for infusion (EMEA/H/C/002532).”

**Zavicefta - ceftazidime / avibactam -**
EMEA/H/C/004027/II/0002

MAH: AstraZeneca AB, Rapporteur: Robert James Hemmings, “Update of section 4.4 of the SmPC to revise the paragraph on limitations of clinical data for hospital acquired pneumonia (HAP) indication, section 4.8 of the SmPC to change the frequency from uncommon to common for thrombocytopia and puritis and section 5.1 of the SmPC to add a new section for HAP/VAP pathogens. The SmPC update is based on the availability of the final CSR for REPROVE (D4281C00001) an updated modelling and simulation report (CAZMS - 09). The Package Leaflet (section 4) is updated accordingly. Study D4281C00001 is a PAES detailed in Annex II.D, therefore an update of Annex II.D is also proposed. In addition, The MAH took the opportunity to add ‘Dilute before use’ to section 5 of the outer Packaging - Carton and to update the list of local representatives in the Package Leaflet.”

**Zeffix - lamivudine -**
EMEA/H/C/000242/II/0068

MAH: Glaxo Group Ltd, Duplicate, Duplicate of Epivir, Rapporteur: Joseph Emmerich, “Update Positive Opinion adopted by consensus on 02.02.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.”
of sections 4.4 and 4.6 of the SmPC to reflect pregnancy clinical outcome data from the Antiretroviral Pregnancy Registry (APR); in addition, an introductory paragraph for pregnancy has been added to section 4.6 of the SmPC in line with the Epivir Product Information (lamivudine for Human Immunodeficiency Virus Indication) (variation EMEA/H/C/000107/II/84).”

Zelboraf - vemurafenib -
EMEA/H/C/002409/II/0039
MAH: Roche Registration Limited, Rapporteur: Filip Josephson, “Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to include the paediatric clinical data from the Zelboraf NO25390 (BRIM-P) after request during assessment as per procedure EMEA/H/C/002409/P46/033.”

Zepatier - elbasvir / grazoprevir -
EMEA/H/C/004126/II/0005
MAH: Merck Sharp & Dohme Limited, Rapporteur: Greg Markey, “Update of section 4.5 of the SmPC in order to update information regarding drug-drug interaction (DDI) of elbasvir/grazoprevir when co-administrated with sunitinib (tyrosine kinase inhibitor). The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to include some editorial changes.”

Weekly start timetable.

Zoely - nomegestrol acetate / estradiol -
EMEA/H/C/001213/II/0037
MAH: Teva B.V., Rapporteur: Joseph Emmerich, “Update of sections 4.4 and 4.5 of the SmPC with revised information regarding interactions with concomitant medications and risk of reduced efficacy. Further, the current paragraph 'laboratory tests' was moved from section 4.5 to section 4.4 of the SmPC. The Package Leaflet has been updated accordingly.”
Request for Supplementary Information adopted on 10.11.2016.

Zoely - nomegestrol acetate / estradiol -
EMEA/H/C/001213/II/0038
MAH: Teva B.V., Rapporteur: Joseph Emmerich, “Update of sections 4.4 and 4.5 of the SmPC concerning Hepatitis C and the risk of elevated

Positive Opinion adopted by consensus on 09.02.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
ALT due to treatment with the HCV combination regimen ombitasvir/paritaprevir/ritonavir co-administered with ethinylestradiol-containing products. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes in the SmPC and Package Leaflet.”
Request for Supplementary Information adopted on 10.11.2016.

**WS1010**
**Descovy**
EMEA/H/C/004094/WS1010/0006
**Genvoya**
EMEA/H/C/004042/WS1010/0017
**Odefsey**
EMEA/H/C/004156/WS1010/0004
MAH: Gilead Sciences International Ltd, Lead Rapporteur: Robert James Hemmings, “Update of section 5.2 of the SmPC in order to provide the final results from Study GS-US-320-1615 “A Phase 1, Open-Label, Parallel-Group, Single Dose Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Subjects with Normal Hepatic Function and Subjects with Severe Hepatic Impairment”.
In addition, the Worksharing applicant (WSA) took the opportunity to update section 4.2 of the SmPC for Descovy to allow dosing in patients with severe hepatic impairment.
The information from the CSR for Study GS-US-320-1615 does lead to the addition or deletion of a safety concern in the corresponding RMPs.”
Request for Supplementary Information adopted on 10.11.2016.

**WS1070**
**Bretaris Genuair**
EMEA/H/C/002706/WS1070/0032
**Eklira Genuair**
EMEA/H/C/002211/WS1070/0032
MAH: AstraZeneca AB, Lead Rapporteur: Nithyanandan Nagercoil, "Update of section 4.3 of the SmPC in order to modify the contraindication section deleting reference to hypersensitivity to atropine or its derivative providing justification for the claim that the chemical structure of aclidinium is unrelated to that of atropine or its derivatives. The Package Leaflet is updated accordingly.”
MAH: AbbVie Ltd., Lead Rapporteur: Joseph Emmerich, “Update of sections 4.3 and 4.5 of the SmPC in order to add information regarding the interaction of lopinavir/ritonavir and ritonavir with lurasidone and ranolazine. In addition, sections 4.4 and 4.5 of the SmPC are updated to add information regarding the interaction with injectable triamcinolone. The Labelling is updated accordingly.”

MAH: Sanofi Clir SNC, Lead Rapporteur: Bruno Sepodes, “Update of section 4.1 to clarify the indication and specify that clopidogrel is indication for the secondary prevention of atherothrombotic events.”

MAH: Merck Sharp & Dohme Limited, Lead Rapporteur: Filip Josephson, “Update of sections 4.2 and 4.8 of the SmPC in order to update the safety information with information on HCV/HBV co-infection, and to add an ADR on hepatitis B reactivation in HCV/HBV co-infected patients as post marketing adverse experience respectively. The Package Leaflet and Labelling are updated accordingly. In addition, the Worksharing applicant (WSA) took the opportunity to bring the PI in line with the latest QRD template version 10 including...
the implementation of the use of combined SmPCs and PLs for PegIntron and ViraferonPeg and the use of combined SmPCs for Intron A in multidose pen.”

| Rezolsta-EMEA/H/C/002819/WS1107/0017/G |
| MAH: Janssen-Cilag International NV, Lead Rapporteur: Johann Lodewijk Hillege, “Update of sections 4.3 and 4.5 of the SmPC with contraindication and information of drug-drug interactions of boosted darunavir with elbasvir/grazoprevir (Zepatier) and with lurasidone (Latuda). The PL was updated accordingly. Update of section 4.5 of the Prezista SmPC regarding the drug-drug interaction of boosted darunavir with corticosteroids in line with the PRAC Recommendation for Rezolsta. In addition, the MAH took the opportunity of this variation, for both products, to add information regarding alfuzosin in section 4.5 in line with section 3, to add inhibition of CYP2D6 for the alfa 1 adrenoreceptor antagonist and to correct the frequency of the adverse event osteonecrosis. Section 4.5 of Prezista was also updated to align information between the different formulations and with Rezolsta. An error was correct in section 5.2. The MAH also took the opportunity to update the Product Information with the lasts QRD templates version 9.1 and 10. The contact of the Dutch local representative in the PL was updated.” |

| WS1110 Kinzalkomb-EMEA/H/C/000415/WS1110/0100 |
| MicardisPlus-EMEA/H/C/000413/WS1110/0102 |
| PritorPlus-EMEA/H/C/000414/WS1110/0110 |
| MAH: Boehringer Ingelheim International GmbH, Lead Rapporteur: Daniela Melchiorri, “Update of section 4.8 to align the hydrochlorothiazide component information with that of the originator. The Package Leaflet is updated accordingly.” |

Weekly start timetable. The Committee adopted a Request for Supplementary information together with a specific timetable.
In addition, Worksharing applicant (WSA) took the opportunity of this procedure to bring the PI in line with the latest QRD template, including combining the SmPC of the different strengths, as well as implement minor editorial changes and reformatting of some sections of the SmPC. The Portuguese local representative in the PL has been updated."

WS1114
Exviera-EMEA/H/C/003837/WS1114/0025
Viekirax-
EMEA/H/C/003839/WS1114/0030
MAH: AbbVie Ltd., Lead Rapporteur: Filip Josephson, "Update of section 4.2 of the SmPC to add that a treatment duration of 8 weeks may be considered in previously untreated genotype 1b-infected patients without advanced fibrosis or cirrhosis supported by the results of the study M15-684 (GARNET). Consequently the section 5.1 of the SmPC is updated to reflect the results of this study. The Package Leaflet is updated accordingly."

Weekly start timetable.

B.5.3. CHMP-PRAC assessed procedures

Adcetris - brentuximab vedotin -
EMEA/H/C/002455/II/0043, Orphan
MAH: Takeda Pharma A/S, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Sabine Straus, "Update of sections 4.8 and 5.1 of the SmPC in order to add data from study C25007. The RMP (version 8.0) was updated accordingly. The submission of the clinical study report fulfils SOB 011 of the conditional marketing authorisation for Adcetris."

ELOCTA - efmoroctocog alfa -
EMEA/H/C/003964/II/0010
MAH: Swedish Orphan Biovitrum AB (publ), Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Rafe Suvarna, "Submission of the final Clinical Study Report of study 997HA307 to investigate PK of the 1000 and 3000 IU vial strengths and evaluate safety of rFVIIIFc. Study 997HA307 is listed as an additional PhV activity (category 3 study, MEA 003) in the Risk Management Plan, therefore an updated RMP is included (ver. 1.5)."
Epclusa - sofosbuvir / velpatasvir -
EMEA/H/C/004210/II/0003
MAH: Gilead Sciences International Ltd,
Rapporteur: Filip Josephson, PRAC Rapporteur:
Ana Sofia Diniz Martins, "Update of section 5.1 of the SmPC in order to reflect on emerging clinical data from study GS-US-342-1202 investigating efficacy and safety in subjects with chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV)-1 coinfection. In addition, minor editorial changes are implemented throughout the Product Information."
Request for Supplementary Information adopted on 15.12.2016.

Erivedge - vismodegib -
EMEA/H/C/002602/II/0032
MAH: Roche Registration Limited, Rapporteur:
Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, "Update of section 5.3 of the SmPC in order to reflect non-clinical carcinogenicity studies (MEA 003):

- Study 13-0322 is a 26-Week Oral Gavage Carcinogenicity Study with Vismodegib in Hemizygous CByB6F1-Tg(HRAS)2Jic Mice.

- Study 13-0323 is a 104-Week and 52-Week with a 12-Week Recovery Phase Oral Gavage Carcinogenicity Study with Vismodegib in Sprague Dawley Rats.

The RMP (RMP 12.0) has been consequently updated. Furthermore, additional routine changes (including some resulting from the assessment of RMP version 11) have been introduced."

EVARREST - human fibrinogen / human thrombin - EMEA/H/C/002515/II/0027/G
MAH: Omrix Biopharmaceuticals N. V.,
Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Group of variations consisting of:
1) Submission of the final results for study BIOS-13-005 updating the efficacy and safety information
2) Submission of the final results for study BIOS-13-004 updating the efficacy and safety information
3) Submission of the final results for study 400-
12-002 updating the efficacy and safety information
4) Submission of the final results for study 400-12-005 updating the safety information
5) Update of section 5.1 of the SmPC to include further information on main existing efficacy studies
Sections 4.8, 5.1 of the SmPC are affected by this group of variations. In addition, the Product Information has been updated in accordance with the QRD template, version 10 and Guideline on core SmPC for plasma-derived fibrin/sealant/haemostatic products (EMA/CHMP/BPWP/598816/2010 rev.1). Section 4.2 has been updated regarding the paediatric information for children under the aged of 1 month, according to the EMA waiver. A revised RMP (version 3) is also introduced, including consequential and routine changes.”
Request for Supplementary Information adopted on 10.11.2016.

Herceptin - trastuzumab -
EMEA/H/C/000278/II/0126
MAH: Roche Registration Limited, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, “C.I.13. Submission of the final study report for the PrefHer study (MO22982); a category 3 study in the RMP to fulfill a required additional pharmacovigilance activity.
The PrefHer study is a Phase II, randomized, multicenter, open-label, two-cohort, two-arm, crossover study designed to investigate patient preference for Herceptin intravenous (IV) or Herceptin subcutaneous (SC) administered using the three-weekly (q3w) dosing regimen via the single-use injection device (SID) or from the vial via hand-held syringe, and to compare Health Care professional (HCP) satisfaction and perceived time savings with the two methods of administration in patients with HER2-positive early breast cancer (EBC) in the neoadjuvant/adjuvant setting.
The study also evaluated the safety and efficacy (event-free survival) of Herceptin SC and IV. The crossover design of the study also allowed an evaluation of the safety and tolerability of switching between the Herceptin IV and the Herceptin SC formulations, and vice versa.”
Imbruvica - ibrutinib -
EMEA/H/C/003791/II/0025, Orphan
MAH: Janssen-Cilag International NV,
Rapporteur: Filip Josephson, PRAC Rapporteur:
Julie Williams, "Update of the SmPC section 4.4
to remove the warning and precaution regarding
the effect of Ibrutinib on the QT interval and
section 5.1 to provide additional information
regarding the pharmacodynamic effect of
Ibrutinib on QT/QTs intervals and cardiac
electrophysiology. No changes to the Annex III
Package Leaflet are proposed."
Request for Supplementary Information adopted

Increlex - mecasermin -
EMEA/H/C/000704/II/0044/G, Orphan
MAH: Ipsen Pharma, Rapporteur: Outi Mäki-Ikola,
PRAC Rapporteur: Kirsti Villikka, "Update
of section 4.4 of the SmPC in order to update
the warning regarding antibody response to
injected IGF-1.
Submission of an updated RMP version 9,
including the educational materials, to update
the instructions for antibody testing and
improve wording and advices."

Jardiance - empagliflozin -
EMEA/H/C/002677/II/0026
MAH: Boehringer Ingelheim International
GmbH, Rapporteur: Johann Lodewijk Hillege,
PRAC Rapporteur: Dolores Montero Corominas,
"Submission of the final results of a non-clinical
study on the effect of empagliflozin on blood
ketone level at refeeding after a fasting period,
comparison between refeeding with glucose or
fat in order to fulfil MEA 010. The RMP (version
11.0) is updated accordingly."

Jevtana - cabazitaxel -
EMEA/H/C/002018/II/0034
MAH: Sanofi-Aventis Groupe, Rapporteur:
Alexandre Moreau, PRAC Rapporteur: Claire
Ferard, "Update of sections 4.2, 4.8 and 5.1 of
the SmPC in order to add information from
completed study EFC11785 (Randomized, open-
label multicenter study comparing cabazitaxel at
20 mg/m2 and at 25 mg/m2 every 3 weeks in
combination with prednisone for the treatment
of metastatic castration-resistant prostate
cancer previously treated with a docetaxel-
containing regimen). In addition, the MAH is proposing to modify the wording in section 4.1 of the indication from “hormone refractory” to “castration resistant” prostate cancer to reflect current terminology of the disease in the clinical practice. The RMP is updated accordingly and in accordance with the request from the latest PSUR procedure (EMEA/C/H/002018/PSUSA/000476/201506). Request for Supplementary Information adopted on 10.11.2016, 15.09.2016.

**Levemir - insulin detemir -**  
**EMEA/H/C/000528/II/0084**  
MAH: Novo Nordisk A/S, Rapporteur: Hanne Lomholt Larsen, PRAC Rapporteur: Doris Stenver, "Submission of the summary analysis report on the incidence of neoplasms with the combination of liraglutide and insulin detemir from the cardiovascular outcome trial for Victoza®, trial EX2211-3748 (LEADER®). As a consequence the following important potential risk "Potential risk of malignant neoplasms following combination treatment with insulin detemir + liraglutide + metformin" is deleted from the updated RMP version 18."

**Orkambi - lumacaftor / ivacaftor -**  
**EMEA/H/C/003954/II/0017**  
MAH: Vertex Pharmaceuticals (Europe) Ltd., Rapporteur: Nithyanandan Nagercoil, PRAC Rapporteur: Almath Spooner, "Update of sections 4.8 and 5.1 of the SmPC in order to reflect the long-term safety and efficacy data from Study VX12 809 105. Study VX12 809 105 is a Phase 3, rollover study to evaluate the safety and efficacy of long term treatment with LUM/IVA in subjects aged 12 years and older with cystic fibrosis, homozygous or heterozygous for the F508del CFTR mutation (MEA 001). A new version of the RMP (ver. 2.7) included in this submission has been updated to include the final data from Study 105. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10."

**Perjeta - pertuzumab -**  
**EMEA/H/C/002547/II/0028**  
MAH: Roche Registration Limited, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Doris Stenver, "Final Clinical Study Report the
TRYPHAENA study (BO22280) A randomised, multicentre, multinational Phase II study to evaluate pertuzumab in combination with trastuzumab, given either concomitantly or sequentially with standard anthracycline-based chemotherapy or concomitantly with a nonanthracycline-based chemotherapy regimen, as neoadjuvant therapy for patients with locally advanced, inflammatory or early stage HER2-positive breast cancer.

The RMP (v 8) has been updated to reflect the completion of the study.”

Saxenda - liraglutide - EMEA/H/C/003780/II/0011
MAH: Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst, “Based on submission of the LEADER clinical study results (EX2211-3748: liraglutide effect on and action in diabetes, evaluation of cardiovascular outcome results), changes to sections 4.4, and 5.1 of the SmPC are being proposed in order to update the safety information and include a description of the clinical study outcomes. The Package Leaflet and Labelling are updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to implement minor editorial changes throughout the product information.

The LEADER study was included in the liraglutide RMP as a required pharmacovigilance activity (category 3) to specifically address the important potential risk of cardiovascular disorders in patients with Type 2 Diabetes Mellitus. Updates to the liraglutide RMP based on the study results are also proposed: this variation application fulfils two post-approval commitments in relation to the cardiovascular outcomes trial (MEA 002), as well as to provide additional information on the breast cancer cases found in LEADER (MEA 005). RMP Version 27 was submitted with the application. These liraglutide RMP modifications are in line with the proposed updates to the Saxenda Product Information described above.”

Senshio - ospemifene - EMEA/H/C/002780/II/0012/G
MAH: Shionogi Limited, Rapporteur: Paula
Positive Opinion adopted by consensus on 02.02.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP
Boudewina van Hennik, PRAC Rapporteur: Julie Williams, “- Update of section 4.5 of the SmPC in relation to CYP3A4 based on the results of study E1508I0242 and in fulfilment of PAM 008.
- Update of section 5.2 of the SmPC with information on ospemifene metabolism and excretion based on the results of study E1508I0242 in fulfilment of PAM 013 and PAM 014.
- Update of section 5.2 of the SmPC with information on ospemifene distribution based on the results of studies OSP-PF-046-N and OSP-PF-047-N in fulfilment of PAM 006 and PAM 007.
- Update of section 5.2 of the SmPC based on the results of the bile salt export pump (BSEP) transporter study OSP-PF-041-N in fulfilment of PAM 009.

As a consequence, an updated RMP version 1.2 is provided accordingly.


Request for Supplementary Information adopted on 10.11.2016.

**TAGRISSO - osimertinib -**
**EMEA/H/C/004124/II/0009/G**
MAH: AstraZeneca AB, Rapporteur: Aranzazu Sancho-Lopez, PRAC Rapporteur: Sabine Straus, “Update of SmPC sections 4.2, 4.4, 4.8, 5.1 and 5.2 based on the results from study DS160C00003 (AURA3) and the updated CSRs for studies DS160C00001 (AURAex) and DS160C00002 (AURA2). The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to make editorial changes in the SmPC and Package Leaflet. The application included an updated RMP version 6.0.

The provision of the CSR from study AURA3 addresses the Specific Obligation for Tagrisso and hence the MAH requests the conversion from a Conditional Marketing Authorisation to a Marketing Authorisation not subject to Specific Obligations.

Request for Supplementary Information adopted on 15.12.2016.

**TECFIDERA - dimethyl fumarate -**
**EMEA/H/C/002601/II/0035**
MAH: Biogen Idec Ltd, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, “To update section 4.8 (Undesirable effects) of the recommendation.

See also 9.1.
SmPC under the sub-heading ‘Tabulated summary of adverse reactions’, to include ‘liver function abnormalities’ as an adverse event, observed in the post-marketing setting, and under the sub-heading ‘Hepatic transaminases’ to clarify events not observed in placebo-controlled studies. The package leaflet has been updated accordingly (section 4 under heading ‘Possible side effects’). The MAH has also taken the opportunity to make minor administrative changes in the package leaflet and to review and update the status timelines of clinical and nonclinical study reports in the Risk Management Plan (v8).”
Request for Supplementary Information adopted on 15.12.2016.

**Torisel - temsirolimus -**

EMEA/H/C/000799/II/0063, Orphan

MAH: Pfizer Limited, Rapporteur: Harald Enzmann, PRAC Rapporteur: Martin Huber,
"Submission of final results from Study 3066K1-4438-WW (B1771007) titled “A Randomized Phase 4 Study Comparing 2 Intravenous Temsirolimus (TEMSR) Regimens in Subjects with Relapsed, Refractory Mantle Cell Lymphoma” and fulfilment of obligation to conduct post authorisation measure ANX 027.2.

The MAH also evaluate the toxic effects of interest [e.g., bleeding, infection- and mucositis-related events] for study 3066K1-4438-WW (Post-Marketing Commitment MEA 028) together with a review discussing potential new safety concerns arising from the results.

The RMP (v.3.0) is updated accordingly to add myocardial infarction and cardiovascular events in patient with coexisting cardiovascular conditions as important potential risks, and anaemia, thrombocytopenia, hypercholesterolemia, and hypertriglyceridemia as important identified risks.

In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.”
Request for Supplementary Information adopted on 13.10.2016.

**Tysabri - natalizumab -**

EMEA/H/C/000603/II/0095

Annex to February 2017 CHMP Agenda
MAH: Biogen Idec Ltd, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, “Update of section sections 4.2, 4.3, 4.8, 5.1 and 5.2 of the SmPC based on the results of paediatric studies 101MS028 and 101MS328, in accordance with paediatric investigation plan (EMEA-001095-PIP-12). An updated RMP version 21 was provided as part of the application.” Request for Supplementary Information adopted on 10.11.2016, 15.09.2016, 23.06.2016.

**Vectibix - panitumumab - EMEA/H/C/000741/II/0080**

MAH: Amgen Europe B.V., Rapporteur: Robert James Hemmings, PRAC Rapporteur: Julie Williams, “Update of Annex II in order to provide the results of biomarker analyses from the Vectibix clinical programme including Study 20080763 (according to Supplementary Statistical Analysis Plan dated 20 September 2013), Study 20070820 and Study 20060447. The data submitted are in fulfilment of Annex II obligation ANX017.

The Risk Management Plan (version 21.0) has been updated accordingly.


**Xadago - safinamide - EMEA/H/C/002396/II/0014**

MAH: Zambon SpA, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Almath Spooner, “Submission of study VDD4193 (Safinamide: In Vitro Metabolic Stability in Human Cryopreserved Hepatocytes, by Fatty Acid Amide Hydrolase enzyme (FAAH), Recombinant Human N-Acylethanolamine Acid Amidase (NAAA) and Recombinant Human Acid Ceramidase (ASAH1)) conducted in order to identify specific substances blocking the amidases (inhibitors of amidases) involved in the metabolism of safinamide. The study fulfils the MEA 001.2.” Request for Supplementary Information adopted
Zykadia - ceritinib -  
EMEA/H/C/003819/II/0006/G  
MAH: Novartis Europharm Ltd, Rapporteur: Aranzazu Sancho-Lopez, PRAC Rapporteur: Ulla Wändel Liminga, “Update of section 4.5 of the SmPC based on the final results of the clinical pharmacology study LDK378A2113 and results of a sub-group evaluating the impact of gastric PH-elevating agents on the steady-state PK, efficacy, and safety of ceritinib in ALK-positive NSCLC patients. The provision of the final CSR for study CLDK378A2113 addresses the post-authorisation measure (PAM) MEA 003. In addition, the MAH is proposing a change to the due date for the provision of the final study report for study CLDK378A2110 (PAM, MEA 001). An updated RMP version 3.0 was included as part of the application.”  

WS0992/G  
Relvar Ellipta-  
EMEA/H/C/002673/WS0992/0022/G  
Revinty Ellipta-  
EMEA/H/C/002745/WS0992/0017/G  
MAH: Glaxo Group Ltd, Lead Rapporteur: Concepcion Prieto Yerro, Lead PRAC Rapporteur: Dolores Montero Corominas, “Type II C.I.4:- Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to update the safety information and include data from the HZC113782 (SUMMIT) study (designed to investigate whether FF/VI-Furoate/Vilanterol could improve survival in patients with moderate COPD- chronic obstructive pulmonary disease who had, or were at increased risk for CV-cardiovascular disease). The Package Leaflet and Labelling are updated accordingly. The RMP v.8.1 is updated accordingly.

Type II C.I.4:- Update of section 4.8 of the SmPC in order to add "paradoxical bronchospasm" to the list of adverse reactions. The Package Leaflet and Labelling are updated accordingly.

Type IB C.I.z:- Update of section 5.1 the SmPC in order to correct an error identified in the pharmacodynamic section.”
Request for Supplementary Information adopted on 13.10.2016.

**WS0993**

**Adcirca-EMEA/H/C/001021/WS0993/0025**

**Cialis-EMEA/H/C/000436/WS0993/0085**

MAH: Eli Lilly Nederland B.V., Lead Rapporteur: Concepcion Prieto Yerro, Lead PRAC Rapporteur: Dolores Montero Corominas, “Update of section 4.4 of the SmPC in order to add a new warning on the risk of non-arteritic anterior ischemic optic neuropathy (NAION) based on the final results of study H6D-MC-LVHQ (category 3 study). In addition the Worksharing applicant (WSA) took the opportunity to update the RMP (version 8.0) accordingly.”

Request for Supplementary Information adopted on 13.10.2016.

**WS1101**

**Relvar Ellipta-**

**EMEA/H/C/002673/WS1101/0029**

**Revinty Ellipta-**

**EMEA/H/C/002745/WS1101/0025**

MAH: Glaxo Group Ltd, Lead Rapporteur: Concepcion Prieto Yerro, Lead PRAC Rapporteur: Dolores Montero Corominas, “Update of section 5.1 of the SmPC in order to update the safety information in relation to results of HZC115151 study (A 12-month, open label, randomised, effectiveness study to evaluate fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI) compared with the existing COPD maintenance therapy alone in subjects with Chronic Obstructive Pulmonary Disease (COPD)(an Annex II condition) of the Relvar Ellipta and Revinty Ellipta (92/22mcg strength only). Consequently the RMP version 8.3 is updated.”

**B.5.4. PRAC assessed procedures**

**PRAC Led**

**Adempas - riociguat -**

**EMEA/H/C/002737/II/0014, Orphan**

MAH: Bayer Pharma AG, PRAC Rapporteur: Julie Williams, “Submission of a revised RMP in order to add Off-label use in patients with idiopathic pulmonary pneumonia, with or without pulmonary hypertension as an
important identified risk.”
Request for Supplementary Information adopted on 10.11.2016.

PRAC Led
ATryn - antithrombin alfa -
EMEA/H/C/000587/II/0027
MAH: GTC Biotherapeutics UK Limited,
Rapporteur: Alexandre Moreau, PRAC
Rapporteur: Claire Ferard, “Introduction of the first version of the RMP following request in 6th Annual Re-assessment
EMEA/H/C/000587/S/0021 and second renewal
EMEA/H/C/000587/R/0024”

PRAC Led
Bydureon - exenatide -
EMEA/H/C/002020/II/0042
MAH: AstraZeneca AB, Rapporteur: Kristina Dunder, PRAC Rapporteur: Qun-Ying Yue, “Submission of the updated RMP version 25 following closure and final summary of Exenatide Pregnancy Registry (a prospective, observational study conducted in the United States that actively collected information on exposure to antidiabetic medication during pregnancy and the associated pregnancy outcomes in patients with Type 2 diabetes mellitus). Moreover, the MAH included additional minor updates to the RMP.”

PRAC Led
Eperzan - albiglutide -
EMEA/H/C/002735/II/0028/G
MAH: GlaxoSmithKline Trading Services, PRAC
Rapporteur: Julie Williams, “II: C.I.11.b - Submission of a revised RMP in order to introduce the additional risk minimisation measures addressing the important potential risk of medication errors. Annex II of the Product Information is updated accordingly.

II: C.I.11.b – Update of the RMP to add a new category 3 study as an additional pharmacovigilance activity - Study 204879: A Randomized, Open-label, Active-Controlled, Parallel-Group, Exploratory Study on the Effects of Repeated Doses of Albiglutide compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Subjects with Type 2
Diabetes Mellitus

II: C.I.11.b - Update of the RMP to add a new
category 3 study as an additional
pharmacovigilance activity – Study 201840 - An
Exploratory Randomized, 2-Part, Single-blind,
2-Period Crossover Study Comparing the Effect
of Albiglutide with Exenatide on Regional Brain
Activity Related to Nausea in Healthy Volunteers

II: C.I.11.b – Update of the RMP to add a new
category 3 study as an additional
pharmacovigilance activity – Cross-sectional
survey to assess the effectiveness of the
proposed additional educational materials using
Patient Connect”
Request for Supplementary Information adopted

PRAC Led
Halaven - eribulin -
EMEA/H/C/002084/II/0033
MAH: Eisai Europe Ltd., Rapporteur: Filip
Josephson, PRAC Rapporteur: Ulla Wändel
Liminga, “Update of the RMP version 4.2
following the revision of the protocol for a post-
authorisation study to capture data on the
frequency of resolution and time to resolution of
eribulin-induced or aggravated peripheral
neuropathy from a phase 3 study, E7389-A001-
303 (ACCRU) to an observational study, E7389-
M044-504 (IRENE). The submission of the
corresponding study report to the EMA / PRAC
remains unchanged and is planned during
2019.”
Request for Supplementary Information adopted

PRAC Led
Remicade - infliximab -
EMEA/H/C/000240/II/0201/G
MAH: Janssen Biologics B.V., Rapporteur:
Kristina Dunder, PRAC Rapporteur: Ulla Wändel
Liminga, , “Submission of the clinical study
reports for C0168T45 and C0168T62 together
with an overall summary and evaluation of the
complete long term safety follow-up programs
for Remicade (as per MEA 79).

Study C0168T45 (RESULTS: REMICADE Safety
Under Long term Study) is a Multicenter
International Observational Study of the Long-
term Safety of Infliximab

Study C0168T62 (RESULTS UC: REMICADE Safety Under Long-term Study in Ulcerative Colitis) is a Multicenter International Study of the Long-term Safety of Infliximab in Ulcerative Colitis.

The RMP (RMP 14.0) has been updated to reflect the completion of these studies.”

PRAC Led

Thyrogen - thyrotropin alfa -
EMEA/H/C/000220/II/0088
MAH: Genzyme Europe BV, Rapporteur: Patrick Salmon, PRAC Rapporteur: Almath Spooner, , 
“To transfer the RMP to the latest RMP template. As a consequence, gastrointestinal symptoms, constitutional symptoms, and injection site reactions have been downgraded to identified risks, not categorized as important and therefore have been deleted. In addition, “perceived lower TSH elevation after thyrotropin alfa administration” does not correspond to a safety risk for the patients treated with Thyrogen and was also deleted from the list of important potential risks. Finally, study results and completion date of T4 study have been included and as a consequence, “Use of Thyrogen for remnant ablation in patients originally diagnosed with T4N0-1M0-1 thyroid cancer” was removed from the missing information section. RMP version 9.0 is being submitted.” Request for Supplementary Information adopted on 15.12.2016.

PRAC Led

Troblalt - retigabine -
EMEA/H/C/001245/II/0045
MAH: Glaxo Group Ltd, PRAC Rapporteur: Doris Stenver, , "Submission of a revised RMP (version 18) in order to remove a postauthorization study (PASS) RTG116158, an open label study evaluating the effects of ezogabine/retigabine added to existing anti-epileptic drug(s) on urinary voiding function in subjects with partial onset seizures. In addition, routines change have also been introduced.” Request for Supplementary Information adopted on 10.11.2016.
PRAC Led

**Xeplion - paliperidone -**

**EMEA/H/C/002105/II/0031**

MAH: Janssen-Cilag International NV,
Rapporteur: Kristina Dunder, PRAC Rapporteur: Qun-Ying Yue, "Submission of final study report "Post-Authorization Safety Study Using European Union Databases to Assess the Risk of Cardiovascular and Cerebrovascular Adverse Events in Elderly Patients Treated with Paliperidone Palmitate, Paliperidone Prolonged-Release, and Other Antipsychotics". No changes in the PI are proposed.”

PRAC Led

**Zaltrap - aflibercept -**

**EMEA/H/C/002532/II/0034**

MAH: Sanofi-Aventis Groupe, Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga, "Submission of the final results of the Drug Utilisation Study monitoring the use of Zaltrap in cancer patients including potential off-label use and evaluating the potential for intravitreal use. This fulfils the post authorisation commitment MEA 03."

PRAC Led

**WS1088**

Eucreas-

**EMEA/H/C/000807/WS1088/0057**

Galvus-EMEA/H/C/000771/WS1088/0048

Icandra-

**EMEA/H/C/001050/WS1088/0058**

Jalra-EMEA/H/C/001048/WS1088/0048

Xiliarx-EMEA/H/C/001051/WS1088/0047

Zomarist-

**EMEA/H/C/001049/WS1088/0058**

MAH: Novartis Europharm Ltd, Lead PRAC Rapporteur: Qun-Ying Yue, “Following the outcome of an Article 31 referral procedure for metformin and metformin-containing products (Procedure EMEA/H/A-31/1432), the Applicant was requested to update the Risk Management Plan (RMP) for galvus, Jalra, Xiliarx, Eucreas, Icandra and Zomarist to implement a targeted questionnaire for cases of lactic acidosis.”

B.5.5. CHMP-CAT assessed procedures

**Imlygic - talimogene laherparepvec -**

**EMEA/H/C/002771/II/0008, ATMP**
B.5.6. CHMP-PRAC-CAT assessed procedures

B.5.7. PRAC assessed ATMP procedures

B.5.8. Unclassified procedures and worksharing procedures of type I variations

**WS0934/G**  
**Suboxone-**  
**EMEA/H/C/000697/WS0934/0034/G**  
MAH: Indivior UK Limited, Lead Rapporteur: Martina Weise  
Weekly start timetable.

**WS0984**  
**AZILECT-**  
**EMEA/H/C/000574/WS0984/0073**  
Rasagiline ratiopharm-  
**EMEA/H/C/003957/WS0984/0007**  
MAH: Teva B.V., Lead Rapporteur: Bruno Sepodes  
Request for Supplementary Information adopted on 27.10.2016.  
Positive Opinion adopted by consensus on 09.02.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

**WS1027**  
**Genvoya-**  
**EMEA/H/C/004042/WS1027/0019**  
Striibild-**EMEA/H/C/002574/WS1027/0071**  
**Tybost-EMEA/H/C/002572/WS1027/0030**  
MAH: Gilead Sciences International Ltd, Lead Rapporteur: Robert James Hemmings  
Request for Supplementary Information adopted on 17.11.2016.  
Positive Opinion adopted by consensus on 02.02.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

**WS1030**  
**ANORO-EMEA/H/C/002751/WS1030/0015**  
**Incruse-**  
**EMEA/H/C/002809/WS1030/0014**  
**Laventair-**  
**EMEA/H/C/003754/WS1030/0017**  
**Relvar Ellipta-**  
**EMEA/H/C/002673/WS1030/0028**  
**Revinty Ellipta-**  
**EMEA/H/C/002745/WS1030/0024**  
MAH: Glaxo Group Ltd, Lead Rapporteur: Nithyanandan Nagercoil"The MAH submitted a worksharing procedure in order to enhance patient safety: the MAH is proposing the Weekly start timetable.
addition of pictograms in the user instructions of the Umeclidinium Bromide/Vilanterol, Umeclidinium Bromide and Fluticasone Furoate/Vilanterol to inform the patient/prescriber what the contents of the carton are and that it contains a desiccant sachet which should be discarded when the tray containing the inhaler is first opened. Sections 4.2 of the SmPC and section 6 pf the Package leaflet are therefore amended.

In addition, the MAH took the opportunity to propose the following changes:
- to include a linguistic correction in the Slovakian translation of the section 4.5 of the SmPC of Anoro and Laventair.
- to include two updates related to QRDv10, in the Annex IIIA for outer packaging of Relvar
- to include an amendment to the Slovenian translation of the section 5.2 of the SmPC of high strength of Relvar and Revinty (EU/1/13/886/004, EU/1/13/886/005, EU/1/13/886/006 and EU/1/14/929/004, EU/1/14/929/005, EU/1/14/929/006).

**Weekly start timetable.**

**WS1046**

Ambirix-
EMEA/H/C/000426/WS1046/0082

Twinrix Adult-
EMEA/H/C/000112/WS1046/0116

Twinrix Paediatric-
EMEA/H/C/000129/WS1046/0117

MAH: GSK Biologicals SA, Lead Rapporteur: Robert James Hemmings

**WS1069/G**

Infanrix hexa-
EMEA/H/C/000296/WS1069/0214/G

MAH: GSK Biologicals SA, Lead Rapporteur: Bart Van der Schueren

**WS1080**

Copalia-EMEA/H/C/000774/WS1080/0091

Copalia HCT-
EMEA/H/C/001159/WS1080/0057

Dafiro-EMEA/H/C/000776/WS1080/0093

Dafiro HCT-
EMEA/H/C/001160/WS1080/0058

Exforge-
EMEA/H/C/000716/WS1080/0090

Exforge HCT-
EMEA/H/C/001068/WS1080/0056

MAH: Novartis Europharm Ltd, Lead
<table>
<thead>
<tr>
<th>Rapporteur: Hanne Lomholt Larsen</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WS1081</strong></td>
</tr>
<tr>
<td><strong>Hexacima-</strong></td>
</tr>
<tr>
<td>EMEA/H/C/002702/WS1081/0055</td>
</tr>
<tr>
<td><strong>Hexaxim-</strong></td>
</tr>
<tr>
<td>EMEA/H/W/002495/WS1081/0062</td>
</tr>
<tr>
<td><strong>Hexyon-</strong></td>
</tr>
<tr>
<td>EMEA/H/C/002796/WS1081/0059</td>
</tr>
<tr>
<td><strong>WS1085</strong></td>
</tr>
<tr>
<td><strong>Ceprotin-</strong></td>
</tr>
<tr>
<td>EMEA/H/C/000334/WS1085/0098</td>
</tr>
<tr>
<td><strong>HyQvia-</strong></td>
</tr>
<tr>
<td>EMEA/H/C/002491/WS1085/0034</td>
</tr>
<tr>
<td><strong>Kiovig-</strong></td>
</tr>
<tr>
<td>EMEA/H/C/000628/WS1085/0076</td>
</tr>
<tr>
<td><strong>WS1090/G</strong></td>
</tr>
<tr>
<td><strong>OFEV-</strong></td>
</tr>
<tr>
<td>EMEA/H/C/003821/WS1090/0012/G</td>
</tr>
<tr>
<td><strong>Vargatef-</strong></td>
</tr>
<tr>
<td>EMEA/H/C/002569/WS1090/0014/G</td>
</tr>
<tr>
<td>MAH: Boehringer Ingelheim International GmbH, Lead Rapporteur: Sinan B. Sarac</td>
</tr>
<tr>
<td><strong>WS1094/G</strong></td>
</tr>
<tr>
<td><strong>Eucreas-</strong></td>
</tr>
<tr>
<td>EMEA/H/C/000807/WS1094/0058/G</td>
</tr>
<tr>
<td><strong>Galvus-</strong></td>
</tr>
<tr>
<td>EMEA/H/C/000771/WS1094/0049/G</td>
</tr>
<tr>
<td><strong>Icandira-</strong></td>
</tr>
<tr>
<td>EMEA/H/C/001050/WS1094/0059/G</td>
</tr>
<tr>
<td><strong>Jalra-</strong></td>
</tr>
<tr>
<td>EMEA/H/C/001048/WS1094/0049/G</td>
</tr>
<tr>
<td><strong>Xiliarx-</strong></td>
</tr>
<tr>
<td>EMEA/H/C/001051/WS1094/0048/G</td>
</tr>
<tr>
<td><strong>Zomarist-</strong></td>
</tr>
<tr>
<td>EMEA/H/C/001049/WS1094/0059/G</td>
</tr>
<tr>
<td><strong>WS1098/G</strong></td>
</tr>
<tr>
<td><strong>Olazax-</strong></td>
</tr>
<tr>
<td>EMEA/H/C/001087/WS1098/0019/G</td>
</tr>
<tr>
<td><strong>Olazax Disperzi-</strong></td>
</tr>
<tr>
<td>EMEA/H/C/001088/WS1098/0020/G</td>
</tr>
<tr>
<td>MAH: Glenmark Pharmaceuticals s.r.o., Generic, Duplicate, Generic of Zyprexa, Zyprexa Velotab, Duplicate of Olanzapine Glenmark, Olanzapine</td>
</tr>
</tbody>
</table>
Glenmark Europe, Lead Rapporteur: Alexandre Moreau

**WS1100**

**Adcirca-EMEA/H/C/001021/WS1100/0028**  
**Cialis-EMEA/H/C/000436/WS1100/0088**  
MAH: Eli Lilly Nederland B.V., Lead Rapporteur: Concepcion Prieto Yerro
“This variation is being submitted to update the tadalafil (Adcirca and Cialis) Summary of Product Characteristics to introduce a warning and precaution regarding cases of sudden hearing loss which have been reported after the use of tadalafil, as requested following the outcome of the assessment of a cumulative review on the topic (Post-Authorisation measures 020 and 046 for Cialis and Adcirca). Section 4.4 of the SmPC and section 2 of the Package Leaflet were therefore updated.”

**WS1102**

**Hirobriz Breezhaler-**  
**EMEA/H/C/001211/WS1102/0039**  
**Onbrez Breezhaler-**  
**EMEA/H/C/001114/WS1102/0038**  
**Osil Breezhaler-**  
**EMEA/H/C/001210/WS1102/0038**  
MAH: Novartis Europharm Ltd, Lead Rapporteur: Hanne Lomholt Larsen

**WS1104**

**Epclusa-**  
**EMEA/H/C/004210/WS1104/0008**  
**Harvoni-**  
**EMEA/H/C/003850/WS1104/0047**  
**Sovaldi-EMEA/H/C/002798/WS1104/0039**  
MAH: Gilead Sciences International Ltd, Lead Rapporteur: Filip Josephson

**WS1118/G**

**Helixate NexGen-**  
**EMEA/H/C/000276/WS1118/0185/G**  
**KOGENATE Bayer-**  
**EMEA/H/C/000275/WS1118/0193/G**  
MAH: Bayer Pharma AG, Duplicate, Duplicate of KOGENATE Bayer, Lead Rapporteur: Jan Mueller-Berghaus

**WS1119/G**

**Ibias-**  
**EMEA/H/C/004147/WS1119/0004/G**  
**Kovaltry-**
EMEA/H/C/003825/WS1119/0007/G
MAH: Bayer Pharma AG, Lead Rapporteur: Kristina Dunder

WS1127
Zypadhera-
EMEA/H/C/000890/WS1127/0033
Zyprexa-
EMEA/H/C/000115/WS1127/0122
Zyprexa Velotab-
EMEA/H/C/000287/WS1127/0092
MAH: Eli Lilly Nederland B.V., Duplicate, Duplicate of Olansek, Lead Rapporteur: Outi Mäki-Ikola, “To update section 4.8 of the SmPC and section 4 of the PIL to implement the signal recommendations on ‘Olanzapine – Restless legs syndrome (EPITT no 18659)’ adopted at the 24-27 October 2016 PRAC. The package leaflet is updated accordingly. In addition the EL annexes are brought in line with the EN text.”

B.5.9. Information on withdrawn type II variation / WS procedure

Imlygic - talimogene laherparepvec -
EMEA/H/C/002771/II/0010, ATMP
MAH: Amgen Europe B.V., Rapporteur: Olli Tenhunen, , "Submission of the primary analysis (PA) report for Study 20120324 (A Phase 2, Multicenter, Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec in Subjects with Unresected, Stage IIIIB to IVM1c Melanoma) which is listed as a category 3 pharmacovigilance activity in the Risk Management Plan (RMP).“ Withdrawal request submitted on 09.02.2017.
B.5.10. Information on type II variation / WS procedure with revised timetable

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

B.6.1. Start of procedure for New Applications: timetables for information

B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information

B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information

- cladribine - EMEA/H/C/004230
  , treatment of highly active relapsing-remitting multiple sclerosis (MS)
  List of Questions adopted on 10.11.2016.

- adalimumab - EMEA/H/C/004279
  , treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
  List of Questions adopted on 10.11.2016.

- nusinersen - EMEA/H/C/004312, Orphan
  Applicant: Biogen Idec Ltd, for the treatment of Spinal Muscular Atrophy (SMA).

- atezolizumab - EMEA/H/C/004143
  , treatment of metastatic urothelial treatment of urothelial carcinoma and non-small cell lung cancer (NSCLC)
  List of Questions adopted on 15.09.2016.

B.6.4. Annual Re-assessments: timetables for adoption

B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

Betmiga - mirabegron - EMEA/H/C/002388/R/0026
B.6.6. VARIATIONS – START OF THE PROCEDURE

Timetables for adoption provided that the validation has been completed.

B.6.7. Type II Variations scope of the Variations: Extension of indication

Keytruda - pembrolizumab -
EMEA/H/C/003820/II/0023/G
MAH: Merck Sharp & Dohme Limited,
previously treated with chemotherapy based on the results from study KEYNOTE-045; a phase 3, randomized, active-controlled, multi-site, open-label trial evaluating pembrolizumab administered at 200 mg Q3W versus investigators’ choice of paclitaxel, docetaxel, or vinflunine in patients previously treated with chemotherapy.

Extension of Indication to add treatment of urothelial carcinoma in patients ineligible for cisplatin (not previously treated) based on the results from study KEYNOTE-52; a phase 2, single-arm, multisite, open-label trial of pembrolizumab at 200 mg Q3W in the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.

As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC have been updated and the Package Leaflet has been updated accordingly.

Further, the MAH is proposing a change to section 4.3 of the SmPC to add that only patients with severe hypersensitivity should be excluded from therapy, and a change to section 4.4 of the SmPC adding possible hypersensitivity and anaphylaxis as part of infusion reactions.

The application included an updated RMP version 7.0."

**Stribild - elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil - EMEA/H/C/002574/II/0079**

MAH: Gilead Sciences International Ltd,
Rapporteur: Robert James Hemmings, Co-
Rapporteur: Joseph Emmerich, PRAC
Rapporteur: Rafe Suvarna,"Extension of Indication to include the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years and weighing ≥ 35 kg; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated based on pharmacokinetics, safety and efficacy data through 48 weeks of treatment with Stribild in Study GS-US-236-0112.
The Package Leaflet and Risk Management Plan (v.12) are updated in accordance.

The requested variation proposed amendments to the Summary of Product Characteristics, Package Leaflet and Risk Management Plan (RMP).

In addition, the Marketing authorisation holder (MAH) took the opportunity to make minor linguistic amendments”

**Truvada - emtricitabine / tenofovir disoproxil - EMEA/H/C/000594/II/0135**

MAH: Gilead Sciences International Ltd,
Rapporteur: Greg Markey, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Julie Williams, “Extension of Indication to include pre-exposure prophylaxis of HIV in adolescents aged 12 to < 18 years at high risk; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated based on extrapolation of data for emtricitabine, tenofovir disoproxil fumarate, and Truvada in HIV-infected and uninfected subjects.

The Package Leaflet and Risk Management Plan (v.15) are updated in accordance.

The requested variation proposed amendments to the Summary of Product Characteristics, Package Leaflet and Risk Management Plan (RMP).

In addition, the Marketing authorisation holder (MAH) took the opportunity to make minor linguistic amendments”

**Zydelig - idelalisib - EMEA/H/C/003843/II/0032/G**

MAH: Gilead Sciences International Ltd,
Rapporteur: Filip Josephson, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Rafe Suvarna,C.I.6. Extension of Indication: Extension of the approved chronic lymphocytic leukemia (CLL) indication for Zydelig to include its use in combination with bendamustine and rituximab based on the results of the primary analysis of pivotal Study GS-US-312-0115 “a Phase 3, randomized, double-blind, controlled study evaluating the efficacy and safety of
idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia" as a consequence, sections 4.1, 4.8, and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance.

In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. The RMP version 2.2 has also been submitted.

C.I.13: Submission of the final report from study 101-08, a phase 2, single-arm study evaluated idelalisib monotherapy and in combination with rituximab in elderly subjects with previously untreated CLL or small lymphocytic lymphoma. Inclusion of this report provides additional safety data to support the evaluation of the use of idelalisib in patients with CLL. Submission of this report is also made in fulfilment of PAM008.

C.I.13: Submission of the final report from study GS-US-312-0123, a phase 3 randomized study evaluated idelalisib in combination with bendamustine and rituximab in subjects with previously untreated CLL. Inclusion of this report is supportive of a complete safety evaluation concerning the use of this combination in patients with CLL.”

**WS1078**
**Komboglyze-**
**EMEA/H/C/002059/WS1078/0035**
**Onglyza-**
**EMEA/H/C/001039/WS1078/0041**
MAH: AstraZeneca AB, Lead Rapporteur: Johann Lodewijk Hillege"Extension of Indication to include the use of a triple combination therapy (saxagliptin, metformin and dapagliflozin) as adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type 2 diabetes mellitus, when metformin together with dapagliflozin, do not provide adequate glycaemic control. Editorial changes are made throughout the Summary Products Characteristics and Package Leaflets. Furthermore, the Product Information is brought in line with the latest QRD template version 10 for Onglyza.”
### B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

<table>
<thead>
<tr>
<th>Product</th>
<th>Reference</th>
<th>MAH</th>
<th>Rapporteur</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advate - octocog alfa</td>
<td>EMEA/H/C/000520/II/0083/G</td>
<td>Baxter AG</td>
<td>Jan Mueller-Berghaus</td>
</tr>
<tr>
<td>Aflunov - prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)</td>
<td>EMEA/H/C/002094/II/0032</td>
<td>Seqirus S.r.l</td>
<td>Daniela Melchiorri</td>
</tr>
<tr>
<td>Afstyla - lonoctocog alfa</td>
<td>EMEA/H/C/004075/II/0001</td>
<td>CSL Behring GmbH</td>
<td>Jan Mueller-Berghaus</td>
</tr>
<tr>
<td>Azopt - brinzolamide</td>
<td>EMEA/H/C/000267/II/0064/G</td>
<td>Alcon Laboratories (UK) Ltd</td>
<td>Concepcion Prieto Yerro</td>
</tr>
<tr>
<td>Cetrotide - cetrorelix acetate</td>
<td>EMEA/H/C/000233/II/0056</td>
<td>Merck Serono Europe Limited</td>
<td>Martina Weise</td>
</tr>
<tr>
<td>CIAMBRA - pemetrexed</td>
<td>EMEA/H/C/003788/II/0002/G</td>
<td>Menarini International Operations Luxembourg S.A.</td>
<td>Juris Pokrotnieks</td>
</tr>
<tr>
<td>Focliivia - influenza virus surface antigens (inactivated) of strain A/Vietnam/1194/2004 (H5N1)</td>
<td>EMEA/H/C/001208/II/0027</td>
<td>Seqirus S.r.l</td>
<td>Daniela Melchiorri</td>
</tr>
<tr>
<td>Galafold - migalastat</td>
<td>EMEA/H/C/004059/II/0005, Orphan</td>
<td>Amicus Therapeutics UK Ltd</td>
<td>Johann Lodewijk Hillege</td>
</tr>
<tr>
<td>Imbruvica - ibrutinib</td>
<td>EMEA/H/C/003791/II/0032/G, Orphan</td>
<td>Janssen-Cilag International NV</td>
<td>Filip Josephson</td>
</tr>
<tr>
<td>Keytruda - pembrolizumab</td>
<td>EMEA/H/C/003820/II/0026/G</td>
<td>Merck Sharp &amp; Dohme Limited</td>
<td></td>
</tr>
</tbody>
</table>
Rapporteur: Daniela Melchiorri,

**Mysimba - naltrexone hydrochloride / bupropion hydrochloride -**
EMEA/H/C/003687/II/0013/G
MAH: Orexigen Therapeutics Ireland Limited,
Rapporteur: Hanne Lomholt Larsen,

**OPDIVO - nivolumab -**
EMEA/H/C/003985/II/0031/G
MAH: Bristol-Myers Squibb Pharma EEIG,
Rapporteur: Aranzazu Sancho-Lopez,

**Orkambi - lumacaftor / ivacaftor -**
EMEA/H/C/003954/II/0018/G
MAH: Vertex Pharmaceuticals (Europe) Ltd.,
Rapporteur: Nithyanandan Nagercoil,

**Simponi - golimumab -**
EMEA/H/C/000992/II/0074/G
MAH: Janssen Biologics B.V., Rapporteur: Kristina Dunder,

**TachoSil - human thrombin / human fibrinogen -**
EMEA/H/C/000505/II/0077/G
MAH: Takeda Austria GmbH, Rapporteur: Jan Mueller-Berghaus,

**Thyrogen - thyrotropin alfa -**
EMEA/H/C/000220/II/0090
MAH: Genzyme Europe BV, Rapporteur: Patrick Salmon,

**Vectibix - panitumumab -**
EMEA/H/C/000741/II/0084
MAH: Amgen Europe B.V., Rapporteur: Robert James Hemmings

**Vimizim - elosulfase alfa -**
EMEA/H/C/002779/II/0017/G, Orphan
MAH: BioMarin Europe Ltd, Rapporteur: Johann Lodewijk Hillege,

**WS1124**
Fertavid-
EMEA/H/C/001042/WS1124/0034
Puregon-
EMEA/H/C/000086/WS1124/0092
MAH: Merck Sharp & Dohme Limited, Lead Rapporteur: Nithyanandan Nagercoil
B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Eperzan - albiglutide -
EMEA/H/C/002735/II/0031
MAH: GlaxoSmithKline Trading Services,
Rapporteur: Kristina Dunder, "Update of sections 4.4 and 4.8 of the SmPC in order to add angioedema with frequency ‘rare’ and to include a warning concerning hypersensitivity reactions in general.
The Package Leaflet is updated accordingly.

In addition, the Marketing authorisation holder took the opportunity to implement minor editorial amendments throughout the Product Information."

Glivec - imatinib -
EMEA/H/C/000406/II/0108
The provision of the study report addresses the post-authorisation measure MEA 162.8."

Hetlioz - tasimelteon -
EMEA/H/C/003870/II/0008, Orphan
MAH: Vanda Pharmaceuticals Ltd., Rapporteur: Greg Markey, "Update of section 4.5 of the SmPC with the deletion of the CYP2C19 statement and the removal of the commitment to conduct a human CYP2C19 Drug-Drug Interaction Study to evaluate the single-dose pharmacokinetics of tasimelteon 20 mg alone and in combination with a CYP2C19 inhibitor, omeprazole, at steady-state from the Risk Management Plan (RMP)."

IDELVION - albutrepenonacog alfa -
EMEA/H/C/003955/II/0005, Orphan
MAH: CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus, "Update of section 4.8 of the SmPC in order to update the safety information by removing a description of a low titer inhibitor based on information from ongoing study CSL654-3003. The Package Leaflet is updated accordingly."

Lemtrada - alemtuzumab -
EMEA/H/C/003718/II/0017
MAH: Genzyme Therapeutics Ltd, Duplicate, Duplicate of Lemtrada (WD), Rapporteur: Hanne Lomholt Larsen, PRAC Rapporteur: Torbjorn Callreus, "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to update the safety and long term use information in the posology following final results from study CAMMS03409 - An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab (ongoing at the time of the initial MAA) to evaluate the long term safety and efficacy of alemtuzumab in MS patients who received alemtuzumab during prior company-sponsored studies. The RMP version 3.0 has also been submitted. The PL has been updated accordingly.

In addition, the Marketing authorisation holder (MAH) took the opportunity to bring the PI in line with the latest QRD template version 10.0 and to introduce editorial corrections in the PI."

**Lenvima - lenvatinib -**
**EMEA/H/C/003727/II/0008, Orphan**
MAH: Eisai Europe Ltd., Rapporteur: Bart Van der Schueren, "Submission of Clinical Study Report for Study E78080-J081-208"

**Mysimba - naltrexone hydrochloride / bupropion hydrochloride -**
**EMEA/H/C/003687/II/0014**
MAH: Orexigen Therapeutics Ireland Limited, Rapporteur: Hanne Lomholt Larsen, "C.I.13: Submission of the final report from study NaltrexBuprop-1004; a Phase 1, Open-Label, Sequential Design Study to Evaluate the Potential Effect of Multiple Oral Doses of Extended-Release Combination of Naltrexone and Bupropion on the Pharmacokinetics of a Single Oral Dose of Metformin in Healthy Subjects. This study does not lead to changes in the product information."

**Mysimba - naltrexone hydrochloride / bupropion hydrochloride -**
**EMEA/H/C/003687/II/0015**
Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects. This study does not lead to changes in the product information.”

**SIRTURO - bedaquiline -**

*EMEA/H/C/002614/II/0021, Orphan*

MAH: Janssen-Cilag International NV,
Rapporteur: Filip Josephson, Update of section 4.4 of the SmPC in order to add delamanid as an example of a drug that prolongs the QT interval following the review of the global safety database for all serious cases received from 28 December 2012 to 30 September 2016. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.”

**Victrelis - boceprevir -**

*EMEA/H/C/002332/II/0041*

MAH: Merck Sharp & Dohme Limited,
Rapporteur: Joseph Emmerich, "Update of sections 4.3 and 4.5 of the SmPC in order to add a new contraindication for the interaction of lurasidone following data obtained from the MAH continuous safety monitoring. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement QRD template version 10, including implementation of the 2D barcode in the PI.”

**WS1072**

Eucreas-

*EMEA/H/C/000807/WS1072/0060*

Galvus-EMEA/H/C/000771/WS1072/0051

Icandra-

*EMEA/H/C/001050/WS1072/0061*

Jalra-EMEA/H/C/001048/WS1072/0051

Xiliarx-EMEA/H/C/001051/WS1072/0050

Zomarist-

*EMEA/H/C/001049/WS1072/0061*

MAH: Novartis Europharm Ltd, Lead Rapporteur: Kristina Dunder”Update of section 5.1 of the SmPC, subsection ‘cardiovascular risk’, with results from a new meta-analysis evaluating the cardiovascular safety of vildagliptin. In addition, the Worksharing applicant (WSA) took the opportunity to bring the annexes in line with the latest QRD template version 10, and to merge the two SmPCs into one single SmPC for Eucreas, Icandra and
B.6.10. CHMP-PRAC assessed procedures

**Champix - varenicline** -
EMEA/H/C/000699/II/0064
MAH: Pfizer Limited, Rapporteur: Hanne Lomholt Larsen, PRAC Rapporteur: Doris Stenver, “Update of sections 4.5 and 5.1 of the SmPC in order to update the safety information based on the final results from study Study A3051078, a Varenicline Pregnancy Cohort Study
This is a prospective cohort study to compare women who use varenicline while pregnant with women who smoke while pregnant with respect to birth outcomes
The Package Leaflet is updated accordingly.
The RMP version 10.1 has also been submitted.
In addition, the Marketing authorisation holder (MAH) took the opportunity to bring the PI in line with the latest QRD template version 10.”

**Edurant - rilpivirine** -
EMEA/H/C/002264/II/0024
MAH: Janssen-Cilag International NV, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Sabine Straus, ”Update of sections 4.2, 4.4, 4.6, 5.1 and 5.2 of the SmPC in order to include information: use of rilpivirine in combination with a background regimen for the treatment of HIV-1 infection during pregnancy and postpartum, without dose adjustment following final results from study TMC114HIV3015 listed as a category 3 study in the RMP. This is a single arm, open-label trial to assess the pharmacokinetics of darunavir/ritonavir, etravirine, and rilpivirine in HIV-1-infected pregnant women.
The Package Leaflet is updated accordingly. The RMP version 7.0 has also been submitted.
In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce the latest renewal date in section 9 of the SmPC and the physical address of the Netherlands Local Operating Company in the PIL section 6.”

**Ganfort - bimatoprost / timolol** -
EMEA/H/C/000668/II/0026
MAH: Allergan Pharmaceuticals Ireland,
Rapporteur: Hanne Lomholt Larsen, PRAC
Rapporteur: Torbjorn Callreus, “Update of section 4.8 as per the PRAC recommendation following the PSUSA assessment. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to update the Product Information in line with the QRD template version 10.0, implement the unique identifier – 2D bar code and correct typo. As per the PRAC recommendation, the updated RMP version 3.2 is also proposed.”

**Keytruda - pembrolizumab -**
EMEA/H/C/003820/II/0025
MAH: Merck Sharp & Dohme Limited, Rapporteur: Daniela Melchiorri, PRAC
Rapporteur: Sabine Straus, “Update of sections 4.2, 4.4 and 4.8 of the SmPC to add a warning for the risk of severe skin reactions and to communicate that Stevens - Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), including fatal cases, have been reported in patients treated with pembrolizumab. The Package Leaflet has been updated accordingly. The application included an updated RMP version 8.0, and a proposed DHPC and communication plan.”

**Zavesca - miglustat -**
EMEA/H/C/000435/II/0056, Orphan
MAH: Actelion Registration Ltd., Rapporteur: Kristina Dunder, PRAC Rapporteur: Qun-Ying Yue, “Submission of 8th NPC (Niemann-Pick type C) Registry report and update of Annex II-D to delete the NPC Registry listed as an obligation to the marketing authorisation.

The RMP version 12.1 has also been submitted to reflect the above changes. In addition, the Marketing authorisation holder took the opportunity to introduce minor changes and bring the Product Information and Annex A in line with the latest QRD template version 10.”

**WS1117/G**
**Stocrin-**
EMEA/H/C/000250/WS1117/0110/G
**Sustiva-**
EMEA/H/C/000249/WS1117/0139/G
MAH: Bristol-Myers Squibb Pharma EEIG, Lead Rapporteur: Bruno Sepodes, Lead PRAC Rapporteur: Ana Sofia Diniz Martins”C.I.4 (Type
II) - Update of sections 4.4, 4.5 and 5.1 of the SmPC in order to add a warning and update the safety information on QTc prolongation based on the final results from study AI266959; this is an interventional study to determine the concentration-electrocardiographic effects of efavirenz in healthy subjects enriched for cyp2b6 polymorphisms; the Package Leaflet is updated accordingly. The RMP version 8 has also been submitted.

C.I.4 (Type II) – Update of sections 4.4 and 4.8 to add catatonia as a Psychiatric symptom following an assessment of catatonia cases reported in the literature and via the United States (US) Food and Drug Administration Adverse Event Reporting System (FAERS).”

WS1130/G
Efficib-
EMEA/H/C/000896/WS1130/0081/G
Janumet-
EMEA/H/C/000861/WS1130/0081/G
Ristfor-
EMEA/H/C/001235/WS1130/0068/G
Velmetia-
EMEA/H/C/000862/WS1130/0084/G
MAH: Merck Sharp & Dohme Limited, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Menno van der Elst,
“C.I.11.b: Submission of an updated RMP version 7 in order to add a targeted questionnaire related to lactic acidosis as part of the outcome of the referral procedure EMEA/H/A-31/1432.

C.I.3.b: Update of sections 4.4 of the SmPC in order to add Bullous pemphigoid as a warning following the PRAC assessment outcome EMEA/H/C/PSUSA/2711/201408; the Labelling is being updated accordingly.”

WS1133/G
Atripla-
EMEA/H/C/000797/WS1133/0121/G
Descovy-
EMEA/H/C/004094/WS1133/0015/G
Eviplera-
EMEA/H/C/002312/WS1133/0081/G
Genvoya-
EMEA/H/C/004042/WS1133/0029/G
Odefsey-
Updates of sections 4.4 and 4.5 of the SmPC for the tenofovir disoproxil fumarate (TDF)-containing products (Viread, Truvada, Atripla, Eviplera, Stribild) which includes the results from Study GS-US-342-1167 and Study GS-US-342-1326.

Update of section 4.5 for the tenofovir alafenamide (TAF)-containing products (Genvoya, Descovy, Odefsey) which include the results from Study GS-US-342-1167.

Study GS-US-342-1167 is a Phase I Study to Evaluate the Pharmacokinetic Drug-Drug Interactions between Sofosbuvir/GS-5815 Fixed Dose Combination (FDC) Tablets and Antiretrovirals Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF; Atripla), Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF; Complera), Dolutegravir (DTG; Tivicay) or Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate (EVG/COBI/FTC/TAF) in Healthy Subjects.

Study GS-US-342-1326, a Phase I Study to Evaluate the Pharmacokinetic Drug-Drug Interaction Potential between Sofosbuvir/GS-5816 (SOF/GS-5816) Fixed-Dose Combination (FDC) Tablet and HIV Antiretroviral Regimens Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (EVG/COBI/FTC/TDF), Ritonavir-boosted Darunavir (DRV/r) plus Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF), Ritonavir-boosted Atazanavir (ATV/r) plus FTC/TDF, Ritonavir/boosted Lopinavir (LPV/r) plus FTC/TDF or Raltegravir plus FTC/TDF.
The Package Leaflet and Risk Management Plan (RMP) are updated accordingly.”

### WS1134
**Truvada**
EMEA/H/C/000594/WS1134/0137

**Viread**
EMEA/H/C/000419/WS1134/0175

MAH: Gilead Sciences International Ltd, Lead Rapporteur: Joseph Emmerich, Lead PRAC Rapporteur: Claire Ferard, “Update of section 4.5 of the SmPC for Viread and Truvada with interactions between emtricitabine (FTC), tenofovir disoproxil fumarate (TDF), ledipasvir, sofosbuvir and dolutegravir based on new clinical pharmacology data from study GS-US-377-1501. This is a Phase 1, open-label, multiple-dose study that evaluated the pharmacokinetic drug-drug interaction potential between Harvoni (ledipasvir [LDV]/sofosbuvir [SOF]) and FTC/TDF+dolutegravir (DTG).

The RMP version 22 for Viread and version 14 for Truvada have also been submitted.”

### WS1141
**Januvia**
EMEA/H/C/000722/WS1141/0056

**Ristaben**
EMEA/H/C/001234/WS1141/0048

**TESAVEL**
EMEA/H/C/000910/WS1141/0056

**Xellevia**
EMEA/H/C/000762/WS1141/0060

MAH: Merck Sharp & Dohme Limited, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Menno van der Elst, , "Update of sections 4.4 of the SmPC in order to add Bullous pemphigoid as a warning following the PRAC assessment outcome EMEA/H/C/PSUSA/2711/201408; the Labelling is being updated accordingly. Consequently, the RMP version 7 is updated accordingly.”

### B.6.11. PRAC assessed procedures

PRAC Led

**Respreeza** - human alpha1-proteinase inhibitor - EMEA/H/C/002739/II/0013

MAH: CSL Behring GmbH, PRAC Rapporteur: Eva A. Segovia, “Submission of an updated RMP version 3.1 in order to include the final safety data from CE1226_3001, which were assessed
in a type II variation (Procedure No. EMEA/H/C/002739/II/0002) and adjustments in the Non-Clinical Safety specification part (Part II, Module SII)."

---

**PRAC Led**

**Tysabri - natalizumab -**

**EMEA/H/C/000603/II/0101**

MAH: Biogen Idec Ltd, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, Submission of the final clinical study report for TYGRIS, a post-marketing safety observational cohort program designed to obtain long-term safety data (approximately 5 years) in subjects with MS treated with natalizumab, and comprising parallel studies 101MS402 (United States and Canada) and 101MS403 (Rest of World). The application included an updated RMP version 23."

---

**PRAC Led**

**Tysabri - natalizumab -**

**EMEA/H/C/000603/II/0102**

MAH: Biogen Idec Ltd, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, “Submission of the final clinical study report for study STRATIFY-2 (101JC402), an observational, longitudinal cohort study designed to gather post-marketing data on the incidence of progressive multifocal leukoencephalopathy (PML) in natalizumab-treated subjects with MS. An updated RMP version 23 was provided accordingly.”

---

**PRAC Led**

**Xiapex - collagenase clostridium histolyticum - EMEA/H/C/002048/II/0089**

MAH: Swedish Orphan Biovitrum AB (publ), Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, "Submission of the final clinical study report for study B1531005, a non-interventional study to evaluate the outcomes (clinical treatment success measured by goniometry assessment, recurrence rate measured by goniometry assessment, subject and physician global assessment of treatment satisfaction, complications resulting from the procedure based on the Adverse Event/Serious Adverse Event (AE/SAE)) of 3 various treatment options for Dupuytren’s contracture, listed as a category 3 study in the RMP. The RMP (version 13.0) is updated accordingly.”
B.6.12. CHMP-CAT assessed procedures

B.6.13. CHMP-PRAC-CAT assessed procedures

B.6.14. PRAC assessed ATMP procedures

B.6.15. Unclassified procedures and worksharing procedures of type I variations

---

**WS0921**
Ebymect-
EMEA/H/C/004162/WS0921/0019
Edistride-
EMEA/H/C/004161/WS0921/0015
Forxiga-
EMEA/H/C/002322/WS0921/0034
Qtern-EMEA/H/C/004057/WS0921/0005
Xigduo-EMEA/H/C/002672/WS0921/0030
MAH: AstraZeneca AB, Lead Rapporteur: Kristina Dunder

**WS1112**
Hexacima-
EMEA/H/C/002702/WS1112/0057
Hexaxim-
EMEA/H/W/002495/WS1112/0063
Hexyon-
EMEA/H/C/002796/WS1112/0061
MAH: Sanofi Pasteur Europe, Duplicate, Duplicate of Hexacima, Lead Rapporteur: Jan Mueller-Berghaus

**WS1131**
Januvia-
EMEA/H/C/000722/WS1131/0055
Ristaben-
EMEA/H/C/001234/WS1131/0047
TESAVEL-
EMEA/H/C/000910/WS1131/0055
Xelevia-EMEA/H/C/000762/WS1131/0059
MAH: Merck Sharp & Dohme Limited, Lead Rapporteur: Johann Lodewijk Hillege

**WS1139/G**
Rivastigmine 1A Pharma-
EMEA/H/C/001181/WS1139/0023/G
Rivastigmine Hexal-
EMEA/H/C/001182/WS1139/0024/G
Rivastigmine Sandoz-
EMEA/H/C/001183/WS1139/0025/G
MAH: 1A Pharma GmbH, Informed Consent of
B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY

B.7.1. Line listing for Variation Type I and Variation Type II (MMD only) post authorisation procedures from the beginning of the year.

B.7.2. Line listing overview of all applications under the centralised procedure (MMD only). line listing - products - authorised, under evaluation, suspended.xls

B.7.3. Opinion on Marketing Authorisation transfer (MMD only).


B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only).

B.7.6. Notifications of Type I Variations (MMD only).

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)

E. Annex E - EMEA CERTIFICATION OF PLASMA MASTER FILES

Disclosure of information related to plasma master files cannot be released at present time as these contain commercially confidential information.
E.1. PMF Certification Dossiers:

E.1.1. Annual Update

E.1.2. Variations:

E.1.3. Initial PMF Certification:

E.2. Time Tables – starting & ongoing procedures: For information

PMF timetables starting and ongoing procedures Tabled in MMD and sent by post mail (folder E).

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver


F.2. Request for scientific opinion on justification of exceptional circumstance and for imperative grounds of public health

G. ANNEX G

G.1. Final Scientific Advice (Reports and Scientific Advice letters):

Disclosure of information related to Scientific Advice cannot be released at present time as these contain commercially confidential information.

Qualification of Biomarkers:

HTA:

G.2. Ongoing procedures

G.3. PRIME

Disclosure of some information related to PRIME cannot be released at present time as these contain commercially confidential information.
G.3.1. List of procedures concluding at 20-23 February 2017 CHMP plenary:

G.3.2. List of procedures starting in Month 20xx for Month 20xx CHMP adoption of outcomes

H. ANNEX H - Product Shared Mailboxes – e-mail address